Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.34 - plasma kallikrein

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abnormalities, Multiple
Hypertension in adult onset diabetes mellitus: abnormal renal hemodynamics and endogenous vasoregulatory factors.
Abortion, Spontaneous
Tissue kallikrein in human placenta in early and late gestation.
Acidosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Acquired Immunodeficiency Syndrome
Inhibition profiles of human tissue kallikreins by serine protease inhibitors.
Kininogens and kallikrein in pruritic papular eruption.
Acute Kidney Injury
Evidence for intrarenal kallikrein storage during chromate-induced acute renal failure in rat.
Inverse relationship between renal and urinary kallikrein during chromate-induced acute renal failure in rat: urinary kallikrein excretion as a possible recovery index.
Pre-stimulation of the kallikrein system in cisplatin-induced acute renal injury: an approach to renoprotection.
Renal and Vascular Effects of Kallikrein Inhibition in a Model of Lonomia obliqua Venom-Induced Acute Kidney Injury.
Urinary kallikrein and pathophysiology of acute renal failure in the rat.
Urinary prostaglandins and kallikrein in the course of acute renal failure.
[The role of the kallikrein-kinin system in the pathogenesis of leptospirosis]
Acute Lung Injury
Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.
Adenocarcinoma
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Human Tissue Kallikreins in Polymorphous Adenocarcinoma: A Polymerase Chain Reaction and Immunohistochemical Study.
Kininase I, kininase II and aminopeptidase levels in patients with gastrointestinal tumors.
[Characteristics of the kallikreins in healthy and malignant (adenocarcinoma) mucous membrane of the human large intestine]
Adenocarcinoma of Lung
Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation.
Adenoma
A case of normotensive primary aldosteronism--comparison with 13 previously experienced cases with hypertension.
Effects of restriction of sodium or administration of fludrocortisone on parotid salivary kallikrein in man.
Urinary excretion of kallikrein before and after operation for aldosterone-producing adenoma.
Urinary kallikrein excretion in patients with primary aldosteronism: differentiation of adrenal adenoma from idiopathic adrenal hyperplasia.
Albuminuria
Exogenous kallikrein protects against diabetic nephropathy.
[The kallikrein-kinin system of the blood in gestosis]
Alkalosis
Effect of metabolic alkalosis and metabolic acidosis on urinary kallikrein excretion of anaesthetized rats: evidence for a role of blood pH as regulator of renal kallikrein secretion.
Urinary kallikrein excretion in Bartter's syndrome.
[Pseudo-Bartter's syndrome induced by surreptitious ingestion of furosemide to lose weight: a case report and possible pathophysiology]
Alzheimer Disease
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia.
Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.
Expression of the kallikrein gene family in normal and Alzheimer's disease brain.
Relationship between the gene polymorphisms of kallikrein-kinin system and Alzheimer's disease in a Hunan Han Chinese population.
[Significance of kallikrein-kinin system in central nervous system diseases].
Amyloidosis
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.
Plasma total prekallikrein/kallikrein activity in rheumatoid arthritis with and without amyloidosis. Increased kaolin-stimulated activity in patients with amyloidosis.
The elusive physiologic role of Factor XII.
Anaphylaxis
Activation of human Hageman factor by a leukocytic protease.
Basophil kallikrein of anaphylaxis (BK-A)--purification and characterization.
Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction.
Contact activation of plasmatic coagulation on polymeric membranes measured by the activity of kallikrein in heparinized plasma.
Contrast media reactions.
Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions.
Release of kallikrein from guinea pig lung during anaphylaxis.
The IgE-dependent release of a Hageman factor cleaving factor from human lung.
The role of basophils in inflammatory reactions.
Anemia
Estimation of plasma kallikrein in sickle-cell anemia, and its relation to the coagulation and fibrinolytic systems.
Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat.
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease.
Anemia, Hemolytic
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]
Anemia, Sickle Cell
Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease.
Aneurysm
Factor XII blockade inhibits aortic dilatation in angiotensin II-infused apolipoprotein E-deficient mice.
von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms.
Angina, Unstable
Activation of leukocytes and of the kallikrein-kinin system in patients with unstable angina pectoris.
Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.
[Hemostasis and pathogenetic therapy of unstable angina pectoris]
Angioedema
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2007.
Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process.
Angioedema in a child with a liver transplant, intussusception, and normal c4 levels.
Angioedema without urticaria: novel findings which must be measured in clinical setting.
Biological therapy in hereditary angioedema: transformation of a rare disease.
Bradykinin-mediated angioedema.
C1 inhibitor function using contact-phase proteases as target: evaluation of an innovative assay.
Chapter 22: Hereditary and acquired angioedema.
Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.
Current treatment options for idiopathic angioedema.
DX-88 and HAE: a developmental perspective.
Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Ecallantide for the treatment of acute attacks in hereditary angioedema.
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
Hereditary angioedema in childhood: an approach to management.
Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.
Lanadelumab for the treatment of hereditary angioedema.
Lanadelumab: First Global Approval.
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency.
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age.
Novelties in the Diagnosis and Treatment of Angioedema.
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Oral medicine case book 64: Some aspects of the pathophysiology of angioedema with special reference to the upper aerodigestive tract.
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
Perioperative Management of Patients With Hereditary Angioedema With Special Considerations for Cardiopulmonary Bypass.
Pharmacotherapy for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review.
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.
The pathogenesis of hereditary angioedema.
The pathophysiology of hereditary angioedema.
Therapeutic Approaches in Hereditary Angioedema.
Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema.
Angioedemas, Hereditary
A mechanism for hereditary angioedema with normal C1-inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
A phase 1 study investigating DX-2930 in healthy subjects.
A rapid method for functional determination of C1 esterase inhibitor in plasma.
A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema.
Assay methods for prekallikrein and kininogens and their applications.
Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE).
Berotralstat: First Approval.
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation.
Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Current treatment options for idiopathic angioedema.
Cyclization of peptides with two chemical bridges affords large scaffold diversities.
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Detection of active kallikrein in induced blister fluids of hereditary angioedema patients.
Discovery of highly potent small molecule kallikrein inhibitors.
DX-88 and HAE: a developmental perspective.
Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.
Ecallantide (Dyax/Genzyme).
Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency.
Ecallantide for treatment of acute attacks of hereditary angioedema.
Ecallantide: A plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
Ecallantide: in acute hereditary angioedema.
Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro.
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.
FDA approves kallikrein inhibitor to treat hereditary angioedema.
Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism.
Hereditary angioedema.
Hereditary angioedema: how to approach it at the emergency department?
Hereditary angioedema: Key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation.
Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.
Immunoblotting of plasma in a pregnant patient with hereditary angioedema.
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Inhibition of plasma kallikrein by a highly specific active site blocking antibody.
Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
Kallikrein Inhibition for Hereditary Angioedema.
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Lanadelumab to treat hereditary angioedema.
Lanadelumab: A Review in Hereditary Angioedema.
Lanadelumab: First Global Approval.
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
Long-term safety outcomes of prekillikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
Managing Chronic Urticaria and Recurrent Angioedema Differently with Advancing Age.
New and rapid functional assay for C1 inhibitor in human plasma.
Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors.
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema.
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
Plasma kallikrein and prorenin in patients with hereditary angioedema.
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease.
Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.
Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat.
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study.
sgp120 and the contact system in hereditary angioedema: A diagnostic tool in HAE with normal C1 inhibitor.
Short review of SEC, a potential dexamethasone-sparing regimen for glioblastoma: spironolactone, ecallantide, clotrimazole.
Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma.
Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma.
Studies on components of the plasma kallikrein and complement systems in plasma and serum samples from normal individuals and patients with hereditary angioedema.
The bradykinin-forming cascade and its role in hereditary angioedema.
The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities.
The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.
Use of a kallikrein inhibitor in the treatment of urticaria and hereditary angioneurotic edema.
Use of recombinant plasma kallikrein inhibitor in hereditary angioedema: a case report and review of the management of the disorder.
Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
[A case of hereditary angioneurotic edema provoked by functional insufficiency of C1-inactivator]
[Monoclonal antibodies for monogenic diseases: a 2019 update].
Anti-Glomerular Basement Membrane Disease
Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress.
Aortic Aneurysm, Abdominal
von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms.
Aortic Valve Stenosis
Kininogenase in kidney after ligation of the ureter and after experimental aortic stenosis.
Arterial Occlusive Diseases
[Evaluation of the combined use of Nico-padutin forte and depot-Padutin in peripheral arterial occlusive disease]
Arteriosclerosis
Kininogenase and kininase activity of the blood in arteriosclerosis.
Arthritis
A critical role for plasma kallikrein in the pathogenesis of autoantibody-induced arthritis.
Activation of the kallikrein-kinin system in arthritis and enterocolitis in genetically susceptible rats: modulation by a selective plasma kallikrein inhibitor.
Bacterial Cell Wall Polymer-Induced Granulomatous Inflammation
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis.
Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat.
Inhibition of plasma kallikrein-kinin system to alleviate renal injury and arthritis symptoms in rats with adjuvant-induced arthritis.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease.
The plasma contact system as a modulator of innate immunity.
The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation.
[High molecular weight kininogen in inflammation and angiogenesis: a review of its properties and therapeutic applications]
Arthritis, Experimental
Effects of a highly selective plasma kallikrein inhibitor on collagen-induced arthritis in mice.
Arthritis, Gouty
Participation of Hageman factor dependent pathways in human disease states.
Arthritis, Psoriatic
Determination of tissue kallikrein and alpha 1-antitrypsin-tissue kallikrein complexes in synovial fluid of patients with rheumatoid, osteo and psoriatic arthritis.
[The treatment of psoriatic arthropathy with a combination of mefenamic and aminocaproic acids]
Arthritis, Reactive
[Kallikrein-kinin system of the synovial fluid in closed injury to the knee joint]
Arthritis, Rheumatoid
Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty's syndrome and systemic lupus erythematosus.
Effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.
Kallikrein in synovial fluid with rheumatoid arthritis.
Regulation of angiogenesis by the kallikrein-kinin system.
Stimulation of bone resorption in cultured mouse calvaria by Lys-bradykinin (kallidin), a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis.
The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.
[Change in the blood kallikrein system in rheumatoid arthritis and deforming osteoarthrosis under the effect of radon baths and the action of decimeter vawes]
Arthrogryposis
Fletcher factor deficiency: report of a new family.
Asthenozoospermia
Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial.
Evaluation of semen quality following kallikrein treatment.
Improvement of sperm motility in patients with asthenozoospermia by kallikrein treatment.
Possible effects of the kallikrein-kinin system on male reproductive functions.
Split ejaculate insemination with and without the addition of kallikrein.
Tamoxifen and kallikrein in therapy of oligoasthenozoospermia: results of a randomized study.
The effect of oral Kallikrein treatment on sperm motility in asthenozoospermia.
Treatment of men with oligoasthenozoospermia and asthenozoospermia with kallikrein.
[Absorption of swine pancreatic kallikrein in humans]
[Andrological, biochemical and endocrinological studies of subfertile men during kallikrein therapy]
[Initial results in the treatment of male fertility disorders with kallikrein: asthenozoospermia]
[Kallikrein therapy in asthenozoospermia]
[New perspectives of in vitro kallikrein treatment of human spermatozoa. I. Study of the hamster ovum penetration test in relation to different andrologic patient groups]
[New perspectives of in vitro kallikrein treatment. II. Study of the hamster ovum penetration test in relation to the kallikrein-kinin system]
[Oral kallikrein-therapy of asthenozoospermia]
[Systemic therapy of male subfertility]
[Therapeutic application of kallikrein in idiopathic oligo- and asthenozoospermia (author's transl)]
[Treatment of fertility disturbances in the male with a combination of mesterolone and kallikrein]
Asthma
Detection of tissue kallikrein in the bronchoalveolar lavage fluid of asthmatic subjects.
Etiology of anaphylactoid responses. The promise of nonionics.
Fine particulate matter increases airway hyperresponsiveness through kallikrein-bradykinin pathway.
IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma: Airway Diseases.
Inhibition of human bronchial kallikrein in asthma.
Localization of immunoreactive tissue kallikrein in human trachea.
Plasma kallikrein amidolytic activity in bronchial asthma.
Primers of contact system activity in asthmatic patients and contrast material reactors.
The plasma contact system in atopic asthma.
[Indicators of the blood kinin system in patients with bronchial asthma during health resort treatment]
Atherosclerosis
Plasmin and kallikrein reduce HDL-induced cholesterol efflux from foam cells.
Profile of genetic variations in severely calcified carotid plaques by whole-exome sequencing.
[Kallikrein in the treatment of patients with obliterative atherosclerosis of the lower limbs and its mechanism of action]
Atrial Fibrillation
Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation.
Autoimmune Diseases
The concept and classification of antiphospholipid/cofactor syndromes.
Azoospermia
Kallikrein in the male reproductive system.
Babesiosis
Soluble parasite antigens from Babesia canis do not directly activate the kallikrein system in dogs infected with Babesia canis.
Bacteremia
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock.
Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man.
Identification of lipopolysaccharide binding site on high molecular weight kininogen.
Plasma kallikrein and Hageman factor in Gram-negative bacteremia.
Bacterial Infections
Binding and activation of human plasma kinin-forming system on the cell walls of Candida albicans and Candida tropicalis.
Bartter Syndrome
A new fluorogenic substrate method for the estimation of kallikrein in urine.
Bartter's syndrome: effect of indomethacin on prostaglandins, urinary kallikrein, renin-angiotensin-aldosterone system, and the response to angiotensin II antagonist.
Bartter's syndrome: urinary prostaglandin E-like material and kallikrein; indomethacin effects.
Effect of indomethacin on urinary kallikrein excretion in Bartter's syndrome of the adult.
Estimation of urinary kininogenase activity using bovine serum low molecular weight kininogen.
Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive diseases.
Kallikrein, kininogen and kinins in control of blood pressure.
Quantitative and qualitative estimation of urinary kallikrein in a patient with Bartter's syndrome.
Some aspects of urinary kallikrein in a patient with Bartter's syndrome.
The kallikrein-kinin system in essential hypertension.
Urinary kallikrein excretion in Bartter's syndrome.
[Endocrinological analysis before and after living-related renal transplantation in a patient of Bartter's syndrome]
Bernard-Soulier Syndrome
Combined occurrence of Bernard-Soulier syndrome and prekallikrein deficiency.
Blister
Comparison of plasma prekallikrein levels in human skin blister and chamber fluids from volunteer subjects and psoriatic patients.
Detection of active kallikrein in induced blister fluids of hereditary angioedema patients.
[Prekallikrein and kininogens in blister fluids in burn patients]
Bradycardia
Hypertensive effect of tissue kallikrein in rostral ventrolateral medulla is mediated by brain kinins.
Brain Diseases
[Kallikrein and prekallikrein content and antitryptic activity in the blood serum in serum hepatitis of varying degrees of severity]
Brain Edema
Evidence for a possible role of the brain kallikrein-kinin system in the modulation of the cerebral circulation.
Mediators of vascular and parenchymal mechanisms in secondary brain damage.
Brain Infarction
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
Brain Injuries
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
Brain Injuries, Traumatic
Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system.
Brain Ischemia
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis.
Selective inhibition of plasma kallikrein protects brain from reperfusion injury.
The Long-Term Outcome Comparison of Different Time-Delayed Kallikrein Treatments in a Mouse Cerebral Ischemic Model.
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing.
[Significance of kallikrein-kinin system in central nervous system diseases].
Breast Neoplasms
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Association of kallikrein expression in nipple aspirate fluid with breast cancer risk.
Biomarkers associated with breast cancer are associated with obesity.
Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women.
Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.
Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines.
Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids.
Expression and enzymatic characterization of recombinant human kallikrein 14.
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.
Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer.
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.
Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer.
Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression.
Kallikrein gene downregulation in breast cancer.
KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer.
Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis.
Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
The combined action of two enzymes in human serum can mimic the activity of cathepsin B.
The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer.
Bronchial Spasm
Etiology of anaphylactoid responses. The promise of nonionics.
Candidiasis
The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney.
Carcinogenesis
Experimental model and immunohistochemical analyses of U87 human glioblastoma cell xenografts in immunosuppressed rat brains.
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.
Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues.
Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis.
Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
Mucin 16 and kallikrein 13 as potential prognostic factors in colon cancer: Results of an oncological 92-multiplex immunoassay.
Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.
Predicting high risk disease using serum and DNA biomarkers.
The new human kallikrein gene family: implications in carcinogenesis.
Carcinoid Tumor
A prospective study of the pathophysiology of carcinoid crisis.
Carcinoid syndrome and serotonin: therapeutic effects of ketanserin.
Flushing in the carcinoid syndrome and plasma kallikrein.
[The ectopic ACTH syndrome]
Carcinoma
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.
Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells.
Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression.
Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma.
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.
Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.
Kallikrein and kinin receptor expression in inflammation and cancer.
Kallikrein system during treatment of hematological malignancies.
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity.
Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1.
Structure-guided design of peptidic ligand for human prostate specific antigen.
[Changes in the proteolytic activity and components of the blood kallikrein-kinin system during the growth and metastasis of experimental neoplasms]
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
Carcinoma, Acinar Cell
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Carcinoma, Endometrioid
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
Carcinoma, Hepatocellular
Plasma prekallikrein levels in patients with hepatocellular carcinoma and liver cirrhosis: a pilot study.
Carcinoma, Non-Small-Cell Lung
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Carcinoma, Ovarian Epithelial
Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Carcinoma, Papillary
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
Carcinoma, Renal Cell
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
Carcinoma, Squamous Cell
Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity.
Cardiac Output, Low
Changes of kallikrein and serotonin in plasma during and after open-heart surgery.
Cardiomegaly
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats.
Down-regulation of bradykinin B2-receptor mRNA in the heart in pressure-overload cardiac hypertrophy in the rat.
Expressions of bradykinin B2-receptor, kallikrein and kininogen mRNAs in the heart are altered in pressure-overload cardiac hypertrophy in mice.
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats.
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats.
Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR.
Protective actions of human tissue kallikrein gene in transgenic rat hearts.
Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene.
Cardiovascular Diseases
A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease.
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
DETERMINATION OF BRADYKININ AND KALLIKREIN AS DIAGNOSTIC METHODS IN CARDIOVASCULAR DISEASE.
Longitudinal Plasma Kallikrein Levels and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC.
Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.
Plasma Kallikrein Inhibitors in Cardiovascular Disease: An Innovative Therapeutic Approach.
Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.
Catalepsy
Participation of prostaglandins in the action of kinins on the central dopaminergic system in the rat. I. The action of kinins on the central dopaminergic system after pretreatment with indomethacin.
Cataract
Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome.
Cerebral Hemorrhage
Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats.
Cerebral Infarction
Experimental therapy with tissue kallikrein against cerebral ischemia.
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Influence of butyphthalide combined with urinary kallikrein in ACI treatment on neuro-cytokines and vascular endothelial function and its clinical effect.
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis.
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
Kallikrein-kinin in stroke, cardiovascular and renal disease.
Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor.
Stroke in a young adult with Fletcher trait.
Study on the clinical efficacy of Human Urinary Kalllikrein in the treatment of acute cerebral infarction according to TOAST classification.
The Long-Term Outcome Comparison of Different Time-Delayed Kallikrein Treatments in a Mouse Cerebral Ischemic Model.
Ultrasound-Mediated Kallidinogenase-Loaded Microbubble Targeted Therapy for Acute Cerebral Infarction.
[A case of cerebral infarction with circulating anticoagulant to Fletcher factor]
[Effect of kallikrein in chronic post-apoplectic cerebral infarct]
Cerebrovascular Disorders
A study of hemostasis in ischemic cerebrovascular disease: IV. A five year follow-up of some blood coagulation parameters also including fibrinopeptide A, factor XII and prekallikrein.
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
Cervical Intraepithelial Neoplasia
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.
Cholecystitis
[Evaluation of the kallikrein-kinin system in patients with chronic impairments of the hepatobiliary system as affected by fasting-diet therapy]
Cholecystitis, Acute
Bradykinin B2 receptors mediate contraction in the normal and inflamed human gallbladder in vitro.
Cholelithiasis
Bradykinin B2 receptors mediate contraction in the normal and inflamed human gallbladder in vitro.
Cholera
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
Chorioamnionitis
Evaluation of potential early markers of chorioamnionitis associated with preterm premature ruptured membranes.
Chronic Urticaria
Cetirizine in the treatment of chronic urticaria.
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria.
Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48/80 and histamine in patients with chronic urticaria and healthy subjects.
Plasma kallikrein amidolytic activity in patients with urticaria.
The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate.
coagulation factor xiia deficiency
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
Activated partial thromboplastin time and minor coagulopathies.
Captopril-induced changes on active and inactive renin in a patient with factor XII congenital deficiency.
Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin.
Evaluation of the clotting defect in a factor XII-deficient kindred.
Evidence against collagen activation of platelet-associated factor XI as a mechanism for initiating intrinsic clotting.
Factor XII and partial prekallikrein deficiencies in a dog with recurrent gastrointestinal hemorrhage.
Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
[Isolated prolongation of the PTT: 2-year retrospective study]
[Use of chromogenic substrates in the clarification of disorders in the early stages of blood coagulation]
Colitis
The plasma contact system as a modulator of innate immunity.
Colitis, Ulcerative
Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Colonic Neoplasms
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
In-silico analysis of kallikrein gene expression in pancreatic and colon cancers.
Colorectal Neoplasms
Biomarker implication of kallikrein-related peptidases as prognostic tissue substrates of poor survival in colorectal cancer.
Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer.
Communicable Diseases
Bradykinin and nitric oxide in infectious disease and cancer.
Severe lung lesions caused by Salmonella are prevented by inhibition of the contact system.
Coronary Artery Disease
Kallikrein-kinin system activation and its interactions with other plasma haemostatic components in the coronary artery disease.
Coronary Disease
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass.
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.
Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women.
Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure.
[Effect of diet therapy on indices of the activity of the plasma kallikrein-kinin system of young and middle-aged ischemic heart disease patients]
[FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE.]
Coronary Occlusion
Aprotinin decreases ischemic damage during coronary revascularization.
Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog.
Cough
Mechanism of irritant-induced cough: studies with a kinin antagonist and a kallikrein inhibitor.
COVID-19
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Crohn Disease
Kallikrein modification with affinity to IgG present in higher amounts than normal in plasma from patients with Crohn's disease.
Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Regulation of angiogenesis by the kallikrein-kinin system.
Cushing Syndrome
Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.
Cystic Fibrosis
Comparative studies on salivary kallikrein from cystic fibrosis patients and controls.
Deficiency of kallikrein activity in plasma of patients with cystic fibrosis.
Increased kallikrein content of saliva from patients with cystic fibrosis of the pancreas. A theory for the pathogenesis of abnormal secretions.
Kallikrein and amylase contents in tissues from a mutant mouse model for human cystic fibrosis.
Normal plasma arginine esterase and the Hageman factor (factor XII) -prekallikrein-kininogen system in cystic fibrosis.
Participation of Hageman factor dependent pathways in human disease states.
Plasma arginine esterase in cystic fibrosis: kinetics of activation, identification as plasma kallikrein, reaction with alpha 2-macroglobulin and comparison with levels in normal plasma.
The kallikrein-kinin system in the colon and lung fluid from a cribriform degeneration (cri) mutant mouse.
The kallikrein-kinin system of sweat in normal and cystic fibrosis subjects.
The radioimmunoassay of human urinary kallikrein and comparisons with kallikrein activity measurements.
Cystitis, Interstitial
Activation of the kallikrein kinin system in interstitial cystitis.
Activation of urinary kallikrein in patients with interstitial cystitis.
Dementia
Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia.
Dementia, Multi-Infarct
Does kallikrein improve the brain function in dementia?
Dementia, Vascular
Apolipoprotein E, angiotensin-converting enzyme and kallikrein gene polymorphisms and the risk of Alzheimer's disease and vascular dementia.
Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia.
Dengue
Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors.
Evaluation of the plasma kinin system in dengue hemorrhagic fever.
Dermatitis
Skin pH is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.
[Experimental studies and clinical experiences with depot padutin in scleroderma and dermatitis atrophicans.]
Dermatitis, Atopic
Decreased cutaneous reactions to kallikrein in patients with atopic dermatitis and psoriasis.
Gamma interferon administration to patients with atopic dermatitis inhibits fibrinolysis and elevates C1 inhibitor.
Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients.
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.
Skin barrier homeostasis in atopic dermatitis: feedback regulation of kallikrein activity.
Skin pH is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.
Skin pH Is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model.
Diabetes Complications
Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.
Diabetes Insipidus
Effect of aprotinin on the renal response to vasopressin in diabetes insipidus rats.
Diabetes Mellitus
Cardiac kinin level in experimental diabetes mellitus: role of kininases.
Contact phase of coagulation in diabetes mellitus after aspirin administration.
Glandular kallikrein, renin and angiotensin converting enzyme of diabetic and hypertensive rats.
Plasma kallikrein activity in human diabetes mellitus.
Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors.
Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus. Relationship to glomerular and tubular function.
Renal hemodynamic abnormalities in patients with short term insulin-dependent diabetes mellitus: role of renal prostaglandins.
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
Urinary active kallikrein excretion and diabetic renal impairments in streptozotocin-treated rats.
Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.
[Clinical treatment of erectile dysfunction in type 2 diabeticpatients in the high-altitude area].
[Effect of no-spa and depot-padutin on the pulse wave spread velocity and skin temperature in patients with diabetes mellitus]
[Endothelium and endogenous fibrinolysis]
[Method of estimating kininogenesis in blood plasma]
[Significance of kallikrein, angiotensin-converting enzyme, and proteolysis inhibitors in vascular complications in diabetes mellitus type 1 in children]
Diabetes Mellitus, Type 1
Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes.
Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus.
Identification of human glandular kallikrein in the beta cell of the pancreas.
Longitudinal Plasma Kallikrein Levels and Their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC.
Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes.
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes.
Renal hemodynamic abnormalities in patients with short term insulin-dependent diabetes mellitus: role of renal prostaglandins.
Urinary kallikrein excretion in insulin-dependent diabetes mellitus and its relationship to glycemic control.
Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.
[Renal hemodynamics and its regulation in recently diagnosed type 1 diabetes mellitus (insulin-dependent diabetes mellitus). The effect of hyperglycemia]
Diabetes Mellitus, Type 2
Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes.
Effect of type 2 diabetes on plasma kallikrein activity after physical exercise and its relationship to post-exercise hypotension.
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes.
Type 2 diabetes elicits lower nitric oxide, bradykinin concentration and kallikrein activity together with higher DesArg(9)-BK and reduced post-exercise hypotension compared to non-diabetic condition.
Urinary kallikrein excretion in non-insulin-dependent diabetes mellitus.
[Clinical treatment of erectile dysfunction in type 2 diabeticpatients in the high-altitude area].
[Endothelium and endogenous fibrinolysis]
Diabetic Cardiomyopathies
Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes.
Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats.
Diabetic Nephropathies
Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes.
Exogenous kallikrein protects against diabetic nephropathy.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Pancreatic Kininogenase Ameliorates Renal Fibrosis in Streptozotocin Induced-Diabetic Nephropathy Rat.
Renal function in the diabetic pregnant rats.
Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.
Urinary kallikrein excretion in early diabetic nephropathy.
[Renal kallikrein in diabetic nephropathy]
Diabetic Retinopathy
Coagulation factors of contact phase of haemostasis are normal in well-controlled type-I diabetic patients despite presence of diabetic retinopathy.
Pancreatic kallikrein protects against diabetic retinopathy in KK Cg-Ay/J and high-fat diet/streptozotocin-induced mouse models of type 2 diabetes.
Plasma kallikrein and diabetic macular edema.
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema.
Plasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats.
Plasma prekallikrein as a risk factor for diabetic retinopathy.
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
The kallikrein system in retinal damage/protection.
The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney.
The kallikrein/kinin system in ocular function.
Thrombosis and Hemorrhage in Diabetic Retinopathy: A Perspective from an Inflammatory Standpoint.
[Effects of oral administration of kallidinogenase (onokrein . P) on the oscillatory potential in the scotopic ERG in diabetic retinopathy (author's transl)]
Disseminated Intravascular Coagulation
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Plasma active renin, inactive renin and kallikrein in patients with disseminated intravascular coagulation.
Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).
Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
[The incidence of consumption coagulopathy in liver cirrhosis]
Dry Eye Syndromes
Elevated Immunoglobulin to Tissue KLK11 in Patients With Sjögren Syndrome.
Ductus Arteriosus, Patent
Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus.
Duodenal Ulcer
[Kallikrein and nonspecific proteases in the saliva of patients with gastric and duodenal ulcers]
Dyslipidemias
Definition of genetic factors in hypertension: a search for major genes, polygenes, and homogeneous subtypes.
Eczema
[The dynamics of the kallikrein-kinin system indices in patients with eczema vera during treatment by the laser photophoresis method with ortofen]
Empyema
[Kallikrein-kinin system in acute empyema of pleura and pyopneumothorax]
Encephalomyelitis
Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.
Endometrial Neoplasms
Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE.
Endotoxemia
Endotoxin, prekallikrein, complement and systemic vascular resistance. Sequential measurements in man.
Endotoxin-induced hypotension in rats is not mediated by prekallikrein activation.
Plasma kallikrein generation in endotoxemia is abolished by ultra high doses of methyl-prednisolone: in vivo studies in a pig model.
Plasma prekallikrein and endotoxemia in liver cirrhosis.
Enterocolitis
Activation of the kallikrein-kinin system in arthritis and enterocolitis in genetically susceptible rats: modulation by a selective plasma kallikrein inhibitor.
Bacterial Cell Wall Polymer-Induced Granulomatous Inflammation
The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation.
[High molecular weight kininogen in inflammation and angiogenesis: a review of its properties and therapeutic applications]
Epilepsy
Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE).
[Significance of kallikrein-kinin system in central nervous system diseases].
Epilepsy, Temporal Lobe
Expression and activity of thimet oligopeptidase (TOP) are modified in the hippocampus of subjects with temporal lobe epilepsy (TLE).
Erectile Dysfunction
Pancreatic kininogenase improves erectile function in streptozotocin-induced type 2 diabetic rats with erectile dysfunction.
Erysipelas
[The use of the kallikrein-kininogen system indices in the prognosis of the development of hemorrhagic erysipelas]
Erythema
Ineffectiveness of aprotinin on psoralen-UVA-(PUVA)-induced erythema.
The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate.
[Kinin system components, free kinins and proteinase inhibitors in the edematous fluids of nephrotic syndrome patients]
Esophageal Squamous Cell Carcinoma
Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.
Essential Hypertension
A comparative study of the measurement of urinary kallikrein by various methods in patients with essential hypertension and patients with proteinuria.
A gene for high urinary kallikrein may protect against hypertension in Utah kindreds.
A simple and sensitive method for determination of human urinary kallikrein activity (kininogenase activity), using human low molecular weight kininogen.
Active kallikrein response to changes in sodium-chloride intake in essential hypertensive patients.
Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study.
Antihypertensive effects of captopril and saralasin in essential and renal hypertension.
Are all individuals equally sensitive in the blood pressure to high salt intake? (Review article).
Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study.
Comprehensive studies on the renal kallikrein-kinin system in essential hypertension.
Correlation of two different assays for urinary kallikrein in normotensive and hypertensive subjects.
Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Decreased urinary kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
Defect in kallikrein-kinin-system in essential hypertension and reduction of blood pressure by orally given kallikrein.
Direct and indirect measurement of urinary kallikrein excretion in patients with essential hypertension and normotensives: relation to age and plasma renin and aldosterone levels.
Effect of furosemide on urinary kallikrein excretion in patients with essential hypertension.
Effect of metoprolol on 24-hour urinary excretion of adrenal steroids and kallikrein in patients with essential hypertension.
Effect of oral potassium on urinary kallikrein excretion in essential hypertension.
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism.
Effects of doxazosin on blood pressure, renin-angiotensin-aldosterone and urinary kallikrein.
Effects of kallidinogenase on urinary kallikrein excretion and plasma prostanoid concentrations in patients with essential hypertension.
Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension.
Effects of perindopril treatment on plasma and urine of kallikrein activity and the stable metabolite of prostaglandin E2 in patients with essential hypertension.
Estimation of urinary kininogenase activity using bovine serum low molecular weight kininogen.
Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.
Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive diseases.
Impaired renal kallikrein activity and elevated blood pressure normalized by orally applied kallikrein in essential hypertension.
Interactions of diuretics with the renal kallikrein-kinin and prostaglandin systems.
Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension.
Kallikrein, kininogen and kinins in control of blood pressure.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension.
Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity.
Low urinary kallikrein excretion and elevated blood pressure normalized by orally kallikrein in essential hypertension.
Malignant hypertension: a syndrome accompanied by plasmatic diminution of low and high molecular weight kininogens.
Malignant hypertension: a syndrome associated with low plasma kininogen and kinin potentiating factor.
Measurement of urinary kallikrein acitvity by kinin radioimmunoassay.
Natriuretic hormones in young hypertensives and in young normotensives with or without a family history of hypertension.
Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship.
Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension.
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Reduced ratio of active-to-total urinary kallikrein in essential hypertension.
Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.
Renal kallikrein-kinin system and prostaglandin in hypertension: their relation to renin-angiotensin-aldosterone system.
Renal kallikrein-kinin, prostaglandin E2, and dopamine systems in young normotensive subjects with a family history of essential hypertension.
Renin, kallikrein and prostaglandin renal systems in normotensive boys with and without a family history of essential hypertension.
Studies on the natriuretic effect of nifedipine in hypertensive patients: increase in levels of plasma atrial natriuretic factor without participation of the renal kallikrein-kinin system.
Study on the renal kallikrein-kinin system in normal and low renin subgroups of essential hypertension.
The effect of aging on urinary kallikrein excretion in normotensive subjects and in patients with essential hypertension.
The excretion of human urinary kallikrein quantity and activity in normal and low renin subgroups of essential hypertension.
The kallikrein-kinin system as a regulator of cardiovascular and renal function.
The method of urinary total kallikrein and prekallikrein measurement, and their urinary excretions in the patients with essential hypertension.
The pathophysiological role of renal dopamine, kallikrein kinin and prostaglandin systems in essential hypertension.
The role of renal prostaglandin E and kallikrein in pathogenesis of essential hypertension.
The role of the renal kallikrein-kinin system in sodium metabolism in normal and low renin essential hypertension.
Thiazide induced hypotension: the role of plasma volume reduction and the urinary kallikrein system.
Urinary excretion of kallikrein before and after operation for aldosterone-producing adenoma.
Urinary excretion of prostaglandin E like material and kallikrein: effects of furosemide.
Urinary excretion of renal prostaglandins, kallikrein, vasopressin and aldosterone in essential hypertension.
Urinary kallikrein activity in the hypertension of renal parenchymal disease.
Urinary kallikrein activity is increased during the first few weeks of exercise training in essential hypertension.
Urinary kallikrein activity is not altered in human essential hypertension.
Urinary kallikrein and salt sensitivity in essential hypertensive males.
Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism.
Urinary kallikrein excretion and sodium metabolism in hypertensive patients.
Urinary kallikrein excretion in Bartter's syndrome.
Urinary kallikrein excretion in children of parents with essential hypertension.
Urinary kallikrein excretion in patients with primary aldosteronism: differentiation of adrenal adenoma from idiopathic adrenal hyperplasia.
Urinary kallikrein excretion is low in malignant essential hypertension.
Urinary kallikrein in mild to moderate essential hypertension.
Urinary kallikrein in normal and hypertensive pregnancies.
Urinary kallikrein in normal pregnancy, pregnancy with hypertension, and toxemia.
Urinary kallikrein in normal renin essential hypertension.
Urinary kallikrein in normotensive subjects and in patients with essential hypertension.
Urinary kallikrein: assay validation and physiological variability.
Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-stage renal and liver disease.
Urinary prostaglandins and kallikrein in essential hypertension.
[Effect of aging on urinary kallikrein excretion in normal subjects and patients with essential hypertension (author's transl)]
[Effects of salt loading on urinary excretion of kallikrein in normotensive subjects and patients with essential hypertension]
[Endogenic activation of prorenin in hypertension]
[Kallikrein and electrolyte excretion in essential hypertension]
[Molecular genetics methods in the study of hereditary essential hypertension]
[Oral administration of extracted kallikrein to patients with essential arterial hypertension]
[Renal kallikrein-kinin system and control of blood pressure (author's transl)]
[Salt-dependence of blood pressure and urinary kallikrein excretion in essential hypertension (author's transl)]
[The effect of physical training on the indices of the general hemodynamics and kinin-kallikrein system activity in hypertension patients]
[The efficacy and tolerance of orally administered kallikrein in patients with essential arterial hypertension]
[The significance of the kallikrein-kinin system in the pathogenesis of essential hypertension]
[Urinary kallikrein and other vasoactive substances in patients with primary aldosteronism and essential hypertension]
[Urinary kallikrein excretion in normal subjects and in patients with essential hypertension]
Exfoliation Syndrome
Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome.
Eye Diseases
The kallikrein system in retinal damage/protection.
Factor XII Deficiency
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
Activated partial thromboplastin time and minor coagulopathies.
Captopril-induced changes on active and inactive renin in a patient with factor XII congenital deficiency.
Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin.
Evaluation of the clotting defect in a factor XII-deficient kindred.
Evidence against collagen activation of platelet-associated factor XI as a mechanism for initiating intrinsic clotting.
Factor XII and partial prekallikrein deficiencies in a dog with recurrent gastrointestinal hemorrhage.
Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation.
Relationship between kallikrein release and factor XII in normal persons and carriers of the Hageman trait.
Two different incubation times for the activated partial thromboplastin time (APTT): a new criterion for diagnosis of lupus anticoagulant.
[Isolated prolongation of the PTT: 2-year retrospective study]
[Use of chromogenic substrates in the clarification of disorders in the early stages of blood coagulation]
Familial Hypophosphatemic Rickets
[Monoclonal antibodies for monogenic diseases: a 2019 update].
Felty Syndrome
Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty's syndrome and systemic lupus erythematosus.
Fetal Resorption
Stereoisomers of alpha-tocopheryl acetate. III. Simultaneous determination of resorption-gestation and myopathy in rats as a means of evaluating biopotency ratios of all-rac- and RRR-alpha-tocopheryl acetate.
Fibrocystic Breast Disease
Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid.
Fibrosarcoma
Increased plasma kallikrein activity and tumour growth suppression associated with intralesional bradykinin injections in hamsters.
Fluorosis, Dental
[Effect of magnesium and selenium on the expression of matrix metalloproteinases-20 and kallikrein 4 in fluorosis mice].
Gastrointestinal Hemorrhage
Factor XII and partial prekallikrein deficiencies in a dog with recurrent gastrointestinal hemorrhage.
Gastrointestinal Neoplasms
Activation of the contact system in ascites from patients with gastrointestinal cancer.
General Adaptation Syndrome
[Effect of kallikrein on the development of the general adaptation syndrome]
Genetic Diseases, Inborn
New insights into hereditary angio-oedema: Molecular diagnosis and therapy.
Gitelman Syndrome
Renin-angiotensin-aldosterone and kallikrein investigations in a patient with resistant hypomagnesaemia due to Gitelman's syndrome.
Glaucoma
The kallikrein system in retinal damage/protection.
[The use of Padutin in the treatment of primary glaucoma]
Glioma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Glomerulonephritis
A case of secondary aldosteronism similar to Bartter's syndrome with no abnormality in renal chloride reabsorption.
A clinical study on urinary kallikrein in patients with renal diseases.
Estimation of urinary kininogenase activity using bovine serum low molecular weight kininogen.
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis.
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
The lupus-susceptibility gene kallikrein downmodulates antibody-mediated glomerulonephritis.
Urinary excretion of prostaglandins (PGE2 and PGF2 alpha) and kallikrein in acute glomerulonephritis.
Urinary kallikrein excretion and renal interstitial damage in mesangial proliferative glomerulonephritis.
Urinary kallikrein excretion in glomerulonephritis and nephrotic syndrome.
[A substrate inhibitor analysis of the urinary excretion of tissue and plasma kallikreins in patients with chronic glomerulonephritis]
[Affinity sorbents with tripeptide morpholine ligands for isolation of proteases]
[The participation of the kallikrein-kinin system in edema formation in glomerulonephritis]
[THe role of the kallikrein-kinin system in the origin of proteinuria in glomerulonephritis]
[Urinary excretion of kallikrein in glomerulonephritis]
[Urinary kallikrein and prostaglandin excretion in patients with chronic glomerulonephritis of hypertensive type and the effect of kallidinogenase on its abnormality]
Glomerulonephritis, Membranoproliferative
[The morphofunctional parallels in arterial hypertension in patients with chronic glomerulonephritis]
Glomerulonephritis, Membranous
Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.
Glossalgia
Chondroitin sulfate and kallikrein in saliva: markers for glossodynia.
Glucose Intolerance
Cardiovascular kinin-generating capability in hypertensive fructose-fed rats.
Glycosuria
Abnormal diurnal urinary sodium and water excretion in diabetic autonomic neuropathy.
Mild renal failure induced by subchronic exposure to molybdenum: urinary kallikrein excretion as a marker of distal tubular effect.
Granuloma
Bacterial Cell Wall Polymer-Induced Granulomatous Inflammation
Inflammatory changes in newly formed vessels of carrageenin-induced granulomas after systemic 5-hydroxytryptamine, bradykinin, kallikrein, or lysolecithin.
Graves Disease
Association of Graves' disease and prekallikrein congenital deficiency in a patient belonging to the first CRM+ prekallikrein-deficient Italian family.
CRM+ severe Fletcher factor deficiency associated with Graves' disease.
Head and Neck Neoplasms
The effect of local radiotherapy on kallikrein activity in saliva secreted by parotid gland in patients with head and neck cancers.
Hearing Loss
[Treatment of neurosensory hearing loss with depot kallikrein]
Heart Defects, Congenital
Clinical presentation and genetic profiles of Chinese patients with velocardiofacial syndrome in a large referral centre.
Heart Failure
Kallikrein teams up with GSK-3beta in heart failure prevention.
Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure.
Protein Biomarkers of Cardiovascular Disease and Mortality in the Community.
The influence of isotonic saline administration on the urinary excretion of kallikrein in rats.
The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.
Urinary kallikrein excretion in congestive heart failure.
Hemarthrosis
A Case of Prekallikrein Deficiency Resulting in Severe Recurrent Mucosal Hemorrhage.
Hematologic Neoplasms
Elevated extracellular trap formation and contact system activation in acute leukemia.
Kallikrein system during treatment of hematological malignancies.
Hemolytic-Uremic Syndrome
Urinary kallikrein in hypertension secondary to hemolytic uremic syndrome: response to diuretic stimulus.
Hemophilia A
Genetics of equine bleeding disorders.
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Hemophilia B
[On the treatment of hemophilia B with kallikrein inactivator (trasylol)]
Hemorrhagic Fever with Renal Syndrome
[Determination of plasma kallikrein and prekallikrein in patients with epidemic hemorrhagic fever and its clinical significance]
Hemostatic Disorders
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Hepatic Insufficiency
1-year survey of patients with advanced liver cirrhosis. Prognostic value of clinical and laboratory indexes identified by the Cox regression model.
Kinin activation in the blood of patients with sepsis.
Plasma prekallikrein as a prognostic indicator in chronic liver insufficiency.
Hepatitis
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.
Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
[Effect of a trypsin and kallikrein inactivator in MHV3 induced experimental hepatitis in mice]
[Evaluation of the kallikrein-kinin system in patients with chronic impairments of the hepatobiliary system as affected by fasting-diet therapy]
[Kallikrein and prekallikrein content and antitryptic activity in the blood serum in serum hepatitis of varying degrees of severity]
[Prekallikrein and kallikrein inhibitors in the blood plasma in viral hepatitis in children]
[RESEARCH ON THE ACTION OF A KALLIKREIN AND TRYPSIN INHIBITOR ON THE COURSE OF EXPERIMENTAL HEPATITIS OF THE MOUSE DUE TO MHV-3.]
[Urinary kallikrein in acute hepatitis and liver cirrhosis]
Hepatitis B
Molecular structure alteration of IgG increased anticomplementary activity of intravenous immunoglobulin.
Hepatitis B, Chronic
Study of contact activation in endemic hepatosplenomegaly.
Hepatitis, Chronic
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Prekallikrein behaviour in chronic active hepatitis and in cirrhotic patients.
Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
Hereditary Angioedema Types I and II
DX-88 and HAE: a developmental perspective.
Herpes Zoster
Effect of high dose oral Kallikrein treatment in men with idiopathic subfertility: evaluation by means of in vitro penetration test of zona free hamster ova.
Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland.
Hydatidiform Mole
Circulating levels of prekallikrein and kallikrein in pregnancy and labor.
Hyperaldosteronism
A case of normotensive primary aldosteronism--comparison with 13 previously experienced cases with hypertension.
A simple and sensitive method for determination of human urinary kallikrein activity (kininogenase activity), using human low molecular weight kininogen.
Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse.
Changes in urinary kallikrein excretion and plasma natriuretic factor in a patient with primary aldosteronism with special reference to adrenal histology.
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism.
Estimation of urinary kininogenase activity using bovine serum low molecular weight kininogen.
Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive diseases.
On the pathogenetic role of prostaglandins in Bartter's syndrome.
Renal kininases in primary aldosteronism.
The kallikrein-kinin system in essential hypertension.
Urinary excretion of kallikrein before and after operation for aldosterone-producing adenoma.
Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism.
Urinary kallikrein excretion and sodium metabolism in hypertensive patients.
Urinary kallikrein excretion in Bartter's syndrome.
Urinary kallikrein excretion in patients with primary aldosteronism: differentiation of adrenal adenoma from idiopathic adrenal hyperplasia.
[Renal kallikrein-kinin system and control of blood pressure (author's transl)]
[Urinary kallikrein and other vasoactive substances in patients with primary aldosteronism and essential hypertension]
Hyperalgesia
Involvement of the kallikrein-kinin system in a model of hyperalgesia in low kallikrein rats.
Hyperemia
Effects of antiproteases (aprotinin and gabexate-mesilate) on the postischemic vascular response of the kidney.
[Inhibition of reactive hyperemia by kallikrein inhibitors in canine oral tissue]
Hyperglycemia
Blockade of early and late retinal biochemical alterations associated with diabetes development by the selective bradykinin B(1) receptor antagonist R-954.
Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus.
Effects of aprotinin on the kallikrein-kinin system in type I diabetes (insulitis).
Urinary and renal tissue kallikrein in the streptozocin-diabetic rat.
Hyperinsulinism
Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.
Evidence for single gene contributions to hypertension and lipid disturbances: definition, genetics, and clinical significance.
Hyperkalemia
Isolated hypoaldosteronism and abnormalities in renin, kallikrein, and prostaglandin.
Studies of the renal vasoactive systems in hyporeninemic hypoaldosteronism.
Hyperlipoproteinemia Type II
Activation of the kallikrein system in hyperbetalipoproteinemia.
Hypernatremia
Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment.
Hyperprolactinemia
Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction.
Hypersensitivity
A case of human seminal plasma allergy sensitized with dog prostatic kallikrein, Can f 5.
Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin.
Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH.
Anaphylaxis and intimate behaviour.
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
Determination of bradykinin-(1-5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation.
Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge.
Human memory CD4+ T cell response to the major dog allergen Can f 5, prostatic kallikrein.
Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions.
Prostatic kallikrein: a new major dog allergen.
Hypertension
A case of normotensive primary aldosteronism--comparison with 13 previously experienced cases with hypertension.
A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease.
A gene for high urinary kallikrein may protect against hypertension in Utah kindreds.
A kallikrein-like enzyme in the aorta of normotensive and hypertensive rats.
A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats.
A novel chromogenic peptide for prekallikrein/kallikrein determination.
Abnormal urinary kallikrein in hypertension is not related to aldosterone or plasma renin activity.
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats.
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
Aldosterone, kallikrein, kininase I and II in normal and hypertension complicated pregnancy.
Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans.
Altered urinary kallikrein excretion in human hypertension.
Altered urinary kallikrein excretion in rats with hypertension.
An ATP-sensitive potassium channel blocker suppresses sodium-induced hypertension through increased secretion of urinary kallikrein.
Antihypertensive effect of MK-421 in rats. Role of the renal kallikrein-kinin system.
Association of the tissue kallikrein gene promoter with ESRD and hypertension.
Atrial natriuretic factor inhibits the hypertension induced by chronic infusion of norepinephrine in conscious rats.
Bradykinin-forming components in Kuwaiti patients with type 2 diabetes.
Brain renin-angiotensin system modifies the blood pressure response to intracerebroventricular cadmium in rats.
Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
Captopril, aldosterone and urinary kallikrein in primary hypertension.
Captopril, kallikrein, and hypertension.
Cardiovascular activities of the bradykinin system.
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
Cardiovascular properties of the kallikrein-kinin system.
Cation excretion and kallikrein secretion by the rat parotid gland in various hypertensive models.
Cellular and functional aspects of the renal kallikrein system in health and disease.
Change in cortical active kallikrein during the onset of Goldblatt hypertension in the rat.
Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study.
Contrasting effects of early and late orchiectomy on hypertension and renal disease in fawn-hooded rats.
Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Definition of genetic factors in hypertension: a search for major genes, polygenes, and homogeneous subtypes.
Determinations of urinary kallikrein and urinary kininase excretion in human hypertension.
Developmental patterns of blood pressure and urinary protein, kallikrein, and prostaglandin E2 in Dahl salt-hypertension-susceptible rats.
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
Diminished renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats.
Does the kinin system mediate in cardiovascular abnormalities? An overview.
Early systemic and renal responses to nephrectomy in normotensive kidney donors.
Effect of ACTH administration on urinary kallikrein excretion in man.
Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure.
Effect of prepuberal gonadectomy upon aldosterone levels in female and male SHR: interaction between blood pressure and kallikrein kinin system.
Effects of altered dietary sodium and desoxycorticosterone acetate on plasma prekallikrein in rats with special reference to hypertension.
Enhanced parotid kallikrein secretion in essential, adrenal, and renoparenchymal hypertension and in advanced renal failure.
Environmental and physiological characteristics in adolescents genetically predisposed to hypertension.
Environmental determinants of urinary kallikrein excretion.
Exaggerated fractional sodium excretion in hypertension with advanced renal disease: the role of renal prostaglandin and kallikrein.
Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases.
Expression and distribution of kallikrein-binding protein mRNA in rat ocular tissues.
Familial hyperaldosteronism.
Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats.
Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah.
Genetics of hypertension: what we know and don't know.
Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease.
Glandular kallikrein, renin and angiotensin converting enzyme of diabetic and hypertensive rats.
Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women.
Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats.
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Hypertension and the bradykinin system.
Hypertension in adult onset diabetes mellitus: abnormal renal hemodynamics and endogenous vasoregulatory factors.
Hypertension in pregnancy. Prostaglandins, kinins and kallikrein.
Immunoreactive glandular kallikrein in plasma during alterations of urinary kallikrein excretion.
Impaired inactive to active kallikrein conversion in human salt-sensitive hypertension.
Inactivation of urinary kallikrein by alpha 1-antitrypsin.
Increased levels of bradykinin and its metabolites in tissues of young spontaneously hypertensive rats.
Increased sensitivity to bradykinin among African Americans.
Increased urinary kallikrein excretion in young borderline hypertensive patients.
Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats.
Isoelectric focusing patterns of urinary kallikrein in Dahl salt-hypertension susceptible and resistant rats.
Kallikrein excretion in Dahl salt-sensitive and salt-resistant rats with native and transplanted kidneys.
Kallikrein excretion in parotid saliva in rats with various forms of arterial hypertension.
Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats.
Kallikrein gene therapy in newborn and adult hypertensive rats.
Kallikrein gene therapy: a new strategy for hypertensive diseases.
Kallikrein, kininogen and kinins in control of blood pressure.
Kallikrein-kinin system in severe experimental hypertension.
Kidney kallikrein and phospholipase activities in Milan spontaneously hypertensive rats.
Kininogenase of the aortic wall in spontaneously hypertensive rats.
Lack of oral kallikrein in lowering systemic blood pressure in primary hypertension.
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats.
Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats.
Loss of sodium modulation of plasma kinins in human hypertension.
Low urinary kallikrein excretion and elevated blood pressure normalized by orally kallikrein in essential hypertension.
Malignant hypertension: a syndrome accompanied by plasmatic diminution of low and high molecular weight kininogens.
Modulation of renin-angiotensin and kallikrein gene expression in experimental hypertension.
Modulation of urinary kallikrein and plasma renin activities does not affect established hypertension in the fawn-hooded rat.
Multigenic human hypertension: evidence for subtypes and hope for haplotypes.
Nephritis blunts urinary kallikrein excretion and aggravates DOCA/NaCl hypertension in rats.
Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship.
Plasma and tissue kallikrein-kinin systems during acute administration of frusemide in normotensive and hypertensive humans.
Plasma kallikrein and diabetic macular edema.
Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats.
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
Plasma kinin levels in acute renovascular hypertension in dogs.
Plasma prekallikrein in hypertension.
Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes.
Plasma renin activity and urinary kallikrein excretion in lead-exposed workers as related to hypertension and nephropathy.
Polymorphisms at the F12 and KLKB1 loci have significant trait association with activation of the renin-angiotensin system.
Potassium supplement upregulates the expression of renal kallikrein and bradykinin B2 receptor in SHR.
Predictors of hypertension. Population studies.
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
Racial differences in renal kallikrein excretion: effect of the ovulatory cycle.
Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure.
Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.
Reduced urinary kallikrein activity in rats developing spontaneous hypertension.
Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is a bradykinin B2-receptor-mediated event.
Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Relation between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man.
Relation of family history of hypertension to platelet aggregation, ratio of total cholesterol to HDL cholesterol and urinary kallikrein excretion.
Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.
Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension.
Renal kallikrein activity in rats developing spontaneous hypertension.
Renal kallikrein activity in spontaneously hypertensive rats.
Renal kallikrein and PGE in the exaggerated fractional Na excretion in patients with chronic renal failure.
Renal kallikrein content of spontaneously hypertensive rats.
Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.
Renal kallikrein in human and experimental diabetes mellitus.
Renal venous output of kinins in patients with hypertension and unilateral renal artery stenosis.
Renin angiotensin aldosterone system, urinary prostaglandins and kallikrein in pregnancy induced hypertension. Evidence for a disregulation of the renin-angiotensin-prostacyclin loop.
Renin, kallikrein and prostaglandin renal systems in normotensive boys with and without a family history of essential hypertension.
Renin-angiotension-aldosterone system, urinary prostaglandins and kallikrein in pregnancy-induced hypertension: evidence for a dysregulation of the renin-angiotensin-prostacyclin loop.
Response of the renal kallikrein-kinin system, intravascular volume, and renal hemodynamics to sodium restriction and diuretic treatment in essential hypertension.
Role of plasma kallikrein in diabetes and metabolism.
Role of tissue kallikrein-kininogen-kinin pathways in the cardiovascular system.
Salivary kallikrein excretion in hypertension.
Significance of the tissue kallikrein promoter and transforming growth factor-beta1 polymorphisms with renal progression in children with vesicoureteral reflux.
Studies on mechanisms of antinephritic action of SA-446 an angiotensin I converting enzyme inhibitor (1). A comparison with actions of spironolactone, kallidinogenase and saralasin.
Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats.
Systemic gene therapy for cardiovascular disease.
Systemic hypertension and the kidney in black patients.
The effect of sodium and potassium loading on urinary kallikrein-like activity in young patients with borderline hypertension.
The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model.
The kallikrein-kinin pathways in hypertension and diabetes.
The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.
The kidney and essential hypertension.
The kinin system in hypertensive pathophysiology.
The pathophysiological role of renal dopamine and kallikrein in deoxycorticosterone acetate (DOCA)-salt treated rats.
The renal kallikrein-kinin system in human and in experimental hypertension.
Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma.
Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases.
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
Total and kallikrein arginine esterase activities in the urine of salt-hypertensive susceptible and resistant rats.
Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia.
Urinary and kidney kallikrein in hypertensive rats.
Urinary excretion of prostaglandins (PGE2 and PGF2 alpha) and kallikrein in acute glomerulonephritis.
Urinary kallikrein activity in the hypertension of renal parenchymal disease.
Urinary kallikrein activity is not altered in human essential hypertension.
Urinary kallikrein activity, renal hemodynamics, and electrolyte handling during chronic beta blockade with propranolol in hypertension.
Urinary kallikrein and hypertension in cadmium-exposed rats.
Urinary kallikrein and kininase activity in normal and complicated by hypertension pregnancy.
Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.
Urinary kallikrein and plasma renin during the reversal of renovascular hypertension in rats.
Urinary kallikrein and prostaglandin response to frusemide in mild hypertension.
Urinary kallikrein excretion after renal transplantation: relationship to hypertension, graft source, and renal function.
Urinary kallikrein excretion and plasma atrial natriuretic peptide in human salt-sensitive hypertension.
Urinary kallikrein excretion and plasma DBH activity in hypertension.
Urinary kallikrein excretion and sodium metabolism in hypertensive patients.
Urinary kallikrein excretion in chronic renal failure: relationship to blood pressure and the acute effect of captopril.
Urinary kallikrein excretion in essential and mineralocorticoid hypertension.
Urinary kallikrein excretion in hypertension.
Urinary kallikrein excretion in neurogenic hypertension in the dogs: possible relationship between kallikrein excretion and catecholamines.
Urinary kallikrein excretion in normal and hypertensive pregnancy at term.
Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8 years later.
Urinary kallikrein excretion is low in malignant essential hypertension.
Urinary kallikrein in hypertension secondary to hemolytic uremic syndrome: response to diuretic stimulus.
Urinary kallikrein in hypertensive animal models.
Urinary kallikrein in normal and hypertensive pregnancies.
Urinary kallikrein in normal pregnancy, pregnancy with hypertension, and toxemia.
Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. A new radioimmunoassay for its direct determination.
Urinary kallikrein levels and hypertension.
Urinary prostaglandin E2 and kallikrein excretion in glucocorticoid hypertension in rats.
Variation of urinary kallikrein excretion during pregnancy and the effects of hypertension.
Vascular kallikrein in deoxycorticosterone acetate-salt hypertensive rats.
Vascular remodeling and the kallikrein-kinin system.
Vascular-derived kinins and local control of vascular tone.
[A case of cerebral infarction with circulating anticoagulant to Fletcher factor]
[Arterial hypertension and urinary kallikrein]
[Changes in the activity of renal intracortical kallikrein during induction of Goldblatt arterial hypertension of the 2 kidney--1 clip type in the rat]
[Changes of components in the kinin system and plasma renin activity during different stages of hypertension in patients treated with captopril]
[Characteristics of changes in the kinin system of blood in hypertensive disease]
[Clinical value of urinary kallikrein determination in obstetrics]
[Concentrations of kininogen and prekallikrein in plasma and activity of plasma renin depending on the type of blood pressure response to captopril in patients with arterial hypertension]
[Contact-activated and immunoreactive prekallikrein in the plasma of patients with hypertension]
[Correlations between plasma levels of kininogen and prekallikrein, plasma renin and urinary excretion of adrenaline and noradrenaline in patients with arterial hypertension]
[Effect of antiadrenergic and myotropic hypotensive agents on the blood kallikrein-kinin system in experimental hypertension]
[Effect of captopril on various components of the kinin system and plasma renin activity in patients with idiopathic arterial hypertension]
[Effect of dilminal D on the hemodynamics in hypertension]
[Effect of heparin and fepromaron on the kallikrein-kinin system in pituitrin-induced hypertension]
[Effect of hypotensive preparations on humoral factors in blood circulation regulation]
[Effect of low-sodium diet and some hypotensive drugs on plasma levels of kininogen and prekallikrein in patients with arterial hypertension]
[Effect of various hypotensive drugs on the plasma level of kininogen and prekallikrein in hypertension]
[Effects of dietary K on blood pressure, prostaglandin, and kallikrein in renovascular hypertensive rats]
[Experimental studies on dietary elements which suppress the development of salt hypertension (I) Effects of potassium salts on sodium metabolism and urinary kallikrein excretion (author's transl)]
[Experimental studies on dietary elements which suppress the development of salt hypertension (II) Effects of protein intake on sodium metabolism and urinary kallikrein excretion (author's transl)]
[Kallikrein and hypertension]
[Kallikrein in urine is an early marker of hypertension]
[Kallikrein versus renin? Changes in kallikrein excretion in experimental hypertension and other conditions]
[Kininogen and prekallikrein in the plasma of patients with hypertension]
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients]
[Oral administration of extracted kallikrein to patients with essential arterial hypertension]
[Peripheral blood renin-angiotensin system indices and the kallikrein-kinin system of the kidneys in hypertension]
[Physiologically active peptides and the regulation of arterial pressure in normal and pathological states]
[Plasma kininogen and prekallikrein activity in hypertensive patients depending on the type and stage of hypertension]
[Relation of atrial natriuretic peptide, the renin-angiotensin-aldosterone system and kinin system in hypertensive and normotensive youngsters with or without a family history of essential arterial hypertension]
[Renal adrenergic beta receptors and experimental neurogenic hypertension]
[Renal kallikrein in diabetic nephropathy]
[Renal kallikrein-kinin system and control of blood pressure (author's transl)]
[Renin-angiotensin-aldosterone system, blood volume, serum uric acid and urinary excretion of prostaglandins and kallikrein in the arterial hypertension induced by pregnancy]
[Role of kallikrein in the pathogenesis of hypertension]
[Selected components of the kallikrein-kinin system and of the renin-angiotensin-aldosterone system in offspring of parents with hypertension]
[Significance of some changes induced in the vasoactive systems of renin and kallikrein during diuretic treatment of arterial hypertension]
[State of the kallikrein-kinin system in blood from the heart ventricle in the dynamics of spontaneous hypertension in the rat]
[Studies of urinary kallikrein in patients with various types of hypertension (relationship to renin-angiotension-aldosterone system (author's transl)]
[Studies on kallikrein activity in diabetic patient with hypertension caused by nephropathy]
[Studies on the pathophysiology of pregnancy induced hypertension--endocrinological analysis by the method of angiotensin II and NaCl loading]
[The activity of the components of the kinin system in renal vein blood in vasorenal arterial hypertension]
[The efficacy and tolerance of orally administered kallikrein in patients with essential arterial hypertension]
[The humoral depressor system function in rheumatic heart defects with arterial hypertension]
[THe role of the kallikrein-kinin system in the origin of proteinuria in glomerulonephritis]
[The significance of urinary kallikrein excretion during treatment of hypertension with diuretics]
[Urinary excretion of kallikrein and hypertension. Statistical comparison of normotensive, hypertensive and borderline cases]
[Urinary kallikrein and plasma renin levels in patients with secondary hypertension]
[Urinary kallikrein and risk of lead poisoning]
[Urinary kallikrein excretion in primary arterial hypertension]
[Urinary kallikrein in hypertension and renovascular hypertension]
[Urinary kallikrein levels during pregnancy]
[Urinary kallikrein quantity and activity of normal pregnant women and toxemia patients in third trimester]
Hypertension, Malignant
Malignant hypertension: a syndrome accompanied by plasmatic diminution of low and high molecular weight kininogens.
Malignant hypertension: a syndrome associated with low plasma kininogen and kinin potentiating factor.
Urinary kallikrein excretion is low in malignant essential hypertension.
Hypertension, Pregnancy-Induced
Altered excretion of prostaglandin and thromboxane metabolites in pregnancy-induced hypertension.
Renin angiotensin aldosterone system, urinary prostaglandins and kallikrein in pregnancy induced hypertension. Evidence for a disregulation of the renin-angiotensin-prostacyclin loop.
Renin-angiotension-aldosterone system, urinary prostaglandins and kallikrein in pregnancy-induced hypertension: evidence for a dysregulation of the renin-angiotensin-prostacyclin loop.
Urinary kallikrein and kininase activity in normal and complicated by hypertension pregnancy.
Urinary kallikrein excretion in normal and hypertensive pregnancy at term.
Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8 years later.
[Kallikrein (urine) in pregnancy-induced hypertension]
[Renin-angiotensin-aldosterone system, blood volume, serum uric acid and urinary excretion of prostaglandins and kallikrein in the arterial hypertension induced by pregnancy]
[Studies on the pathophysiology of pregnancy induced hypertension--endocrinological analysis by the method of angiotensin II and NaCl loading]
Hypertension, Renal
Kallikrein genes: cloning in man and expression in rat renal hypertension.
Renal kallikrein activity and urinary kallikrein excretion in rats with experimental renal hypertension.
Vasoactive peptides in experimental renal hypertension.
Hypertension, Renovascular
A kallikrein-like enzyme in blood vessels of one-kidney, one clip hypertensive rats.
Bilateral urinary kallikrein excretion in the Goldblatt hypertensive rat.
Change in cortical active kallikrein during the onset of Goldblatt hypertension in the rat.
Reduced urinary kallikrein excretion in human renovascular hypertension caused by nonspecific aortoarteritis and other disorders.
Renin-angiotensin and kallikrein-kinin systems in sodium homeostasis and hypertension in rats.
The kallikrein-kinin system in blood pressure homeostasis.
The kallikrein-kinin system in essential hypertension.
Urinary kallikrein and plasma renin during the reversal of renovascular hypertension in rats.
Urinary kallikrein excretion and sodium metabolism in hypertensive patients.
[Kallikrein activity in the renal-vein blood in patients with renovascular hypertension]
[Renal kallikrein: variations in relation to sodium intake and experimental renovascular hypertension (author's transl)]
[Urinary kallikrein and renovascular hypertension in rats]
[Urinary kallikrein in hypertension and renovascular hypertension]
Hyperthyroidism
Contact system activation and high thrombin generation in hyperthyroidism.
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
Hypertriglyceridemia
[Effect of diet therapy on indices of the activity of the plasma kallikrein-kinin system of young and middle-aged ischemic heart disease patients]
[Status of the kallikrein-kinin system of the blood in young and middle-aged patients with ischemic heart disease]
Hypertrophy, Left Ventricular
Changes in plasma prekallikrein activity, blood pressure, and left ventricular thickness in hypertensive and normotensive diabetic rats.
Down-regulation of bradykinin B2-receptor mRNA in the heart in pressure-overload cardiac hypertrophy in the rat.
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.
Hypertrophy, Right Ventricular
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
Hypoaldosteronism
Isolated hypoaldosteronism and abnormalities in renin, kallikrein, and prostaglandin.
Studies of the renal vasoactive systems in hyporeninemic hypoaldosteronism.
[Urinary kallikrein activity in a hyporeninemic hypoaldosteronism syndrome]
Hypokalemia
Therapeutic outcome of primary aldosteronism: adrenalectomy versus enucleation of aldosterone-producing adenoma.
[Pseudo-Bartter's syndrome induced by surreptitious ingestion of furosemide to lose weight: a case report and possible pathophysiology]
Hyponatremia
Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics.
Increased renal kallikrein excretion in SIADH after vincristine therapy.
Increased urinary kallikrein-like activity during ADH-induced hyponatremia in rats.
SIADH and other hyponatremic disorders: diagnosis and therapeutic problems.
Hypophosphatemia, Familial
Early detection of the nephrotoxic effects of industrial chemicals: state of the art and future prospects.
Hypopituitarism
Effect of oral potassium supplements on urinary kallikrein excretion in Sheehan's syndrome.
Hypotension
Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties.
Contaminated heparin associated with adverse clinical events and activation of the contact system.
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors.
Effect of the protease inhibitor aprotinin on renal hemodynamics in the pig.
Effects of experimental hypotension on hemodynamics and renin secretion rate.
Endotoxin-induced hypotension in rats is not mediated by prekallikrein activation.
Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats.
Genetic manipulation and genetic variation of the kallikrein-kinin system: impact on cardiovascular and renal diseases.
Hypertensive effect of tissue kallikrein in rostral ventrolateral medulla is mediated by brain kinins.
Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock.
Kallikrein-kinin system activation by Lonomia obliqua caterpillar bristles: involvement in edema and hypotension responses to envenomation.
Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012.
Kinin, kininogen and kininase levels during acute Babesia bovis (= B. argentina) infection of cattle.
Naloxone attenuates the hypotension induced by Hageman factor.
Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibition.
Suppression of hypotensive responses of captopril and enalapril by the kallikrein inhibitor aprotinin in spontaneously hypertensive rats.
The effect of hemorrhagic hypotension on urinary kallikrein excretion, renin activity, and renal cortical blood flow in the pig.
Thiazide induced hypotension: the role of plasma volume reduction and the urinary kallikrein system.
Urinary kallikrein excretion during inhibition of endogenous angiotensin II in the pig.
Urinary kallikrein excretion in grade school children with high and low blood pressure.
[Use of snake venom proteins in medicine]
Ichthyosis
Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment.
IgA Vasculitis
[Role of the blood kinin system in the pathogenesis of the hemorrhagic syndrome in hemorrhagic vasculitis]
Inappropriate ADH Syndrome
Increased renal kallikrein excretion in SIADH after vincristine therapy.
Increased urinary kallikrein-like activity in the syndrome of inappropriate secretion of antidiuretic hormone.
Infarction, Middle Cerebral Artery
Antithrombotic potential of the contact activation pathway.
Experimental therapy with tissue kallikrein against cerebral ischemia.
Infections
Activation of protein mediators of inflammation and evidence for endotoxemia in Borrelia recurrentis infection.
Acute Babesia bigemina infection: changes in coagulation and kallikrein parameters.
Acute Babesia bovis infections: renal involvement in the hypotensive syndrome.
Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Effect of trasylol on packed cell volume and plasma kallikrein activation in acute Babesia argentina infection of splenectomised calves.
Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii--a model for Rocky Mountain spotted fever.
Induction of vascular leakage and blood pressure lowering through kinin release by a serine proteinase from Aeromonas sobria.
Influence of plasma protease activation on electroimmunoassay and nephelometry of plasma fibronectin in sepsis.
Kallikrein and antibiotics in the treatment of infertile men with genital tract infections.
Kallikrein and kinin receptor expression in inflammation and cancer.
Kallikrein as a pathogenic agent in Plasmodium knowlesi infection in Macaca mulatta.
Kinin activation in the blood of patients with sepsis.
Plasma kallikrein levels in acute Babesia argentina infections in splenectomised and intact calves.
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
Prekallikrein - an emerging therapeutic target for Klebsiella pneumoniae infection?†.
Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?
Soluble parasite antigens from Babesia canis do not directly activate the kallikrein system in dogs infected with Babesia canis.
Structure, kinetics, and function of human and rhesus plasma prekallikreins are similar.
Studies on urinary kallikrein in Trypanosoma brucei infections of the rabbit.
The activation of kallikrein in acute Babesia argentina infections of splenectomised calves.
Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.
[Aspects of hemostasis and the immunology of burns]
[Deleterious pathogenic mechanism involving host response in influenza virus infection in mice]
[Hemostasis in burn patients and treatment with heparin. Relation to prognosis and infection. Pattern of blood levels of prekallikrein, alpha-2-macroglobulin, antithrombin III, plasminogen and alpha-2-antiplasmin]
Infertility
Absorption studies with porcine pancreatic kallikrein in man.
Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting.
Effect of high dose oral Kallikrein treatment in men with idiopathic subfertility: evaluation by means of in vitro penetration test of zona free hamster ova.
Split ejaculate insemination with and without the addition of kallikrein.
The effect of kallikrein on spermatozoal ATP and other semen parameters.
[Successes with kallikrein. Subfertility: chances of therapy]
[Therapy of subfertility with kallikrein]
Infertility, Male
Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebo-controlled trial.
Kallikrein and male subfertility. Usefulness of high-unit kallikrein tablets.
Kallikrein in the male reproductive system.
Kallikrein treatment of male infertility.
Relationship between human seminal kallikrein-kinin system and spermatogenesis.
Tamoxifen and kallikrein in therapy of oligoasthenozoospermia: results of a randomized study.
The treatment of male subfertility with kallikrein.
[Clinical evaluation of kallikrein in male infertility]
[Studies on the treatment of male infertility with kallikrein]
[Treatment of male subfertility with kallikrein]
Inflammatory Bowel Diseases
Activation of the kallikrein-kinin system in arthritis and enterocolitis in genetically susceptible rats: modulation by a selective plasma kallikrein inhibitor.
Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.
Tissue and plasma kallikrein in inflammatory bowel disease.
Influenza, Human
Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.
Insulin Resistance
Bradykinin prevents the apoptosis of NIT-1 cells induced by TNF-? via the PI3K/Akt and MAPK signaling pathways.
Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats.
Intermittent Claudication
[Kallikrein in the treatment of patients with obliterative atherosclerosis of the lower limbs and its mechanism of action]
[The effect of depot padutin on walking tolerance in intermittent claudication.]
Intracranial Aneurysm
Association of kallikrein gene polymorphisms with intracranial aneurysms.
Association of Kallikrein gene polymorphisms with sporadic intracranial aneurysms in the Chinese population.
Saccular intracranial aneurysm disease: distribution of site, size, and age suggests different etiologies for aneurysm formation and rupture in 316 familial and 1454 sporadic eastern Finnish patients.
Intracranial Embolism
Effects of a human urinary kininogenase (SK-827) on cerebral microcirculation after glass bead-induced cerebral embolism in rabbits.
Intracranial Hemorrhages
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
[Influence of a kallikrein inhibitor on the phenomenology of experimental intracranial hemorrhage]
Intracranial Thrombosis
Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report.
Intussusception
Angioedema in a child with a liver transplant, intussusception, and normal c4 levels.
Ischemic Stroke
Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women.
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.
Genetic determinants of activity and antigen levels of contact system factors.
Inhibition of plasma kallikrein mitigates experimental hypertension-enhanced cerebral hematoma expansion.
Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis.
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
Kinins Released by Erythrocytic Stages of Plasmodium falciparum Enhance Adhesion of Infected Erythrocytes to Endothelial Cells and Increase Blood Brain Barrier Permeability via Activation of Bradykinin Receptors.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure.
Joint Diseases
Kallikrein and kinin receptor expression in inflammation and cancer.
Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.
Kidney Diseases
Clotting activities and antigen concentrations of contact factors in kidney disease.
Serum and urinary arginine-esterase activity in paediatric kidney diseases.
Kidney Failure, Chronic
A clinical study on urinary kallikrein in patients with renal diseases.
Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease.
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease.
Low prekallikrein and high angiotensin-converting enzyme activity in patients with chronic renal failure on haemodialysis.
Malignant hypertension: a syndrome accompanied by plasmatic diminution of low and high molecular weight kininogens.
Measurement of urinary kallikrein acitvity by kinin radioimmunoassay.
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Role of renal kallikrein in the increased fractional sodium excretion in the rat remnant kidney model of chronic renal failure.
Role of renal kallikrein in the regulation of blood pressure in the rat remnant kidney model of chronic renal failure.
The role of urinary kininogen in the regulation of kinin generation.
Urinary kallikrein excretion in chronic renal failure: relationship to blood pressure and the acute effect of captopril.
Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-stage renal and liver disease.
[Disruption of regulatory possibilities of the plasma kallikrein-kinin system in chronic kidney failure and during hemodialysis]
[Endocrinological analysis before and after living-related renal transplantation in a patient of Bartter's syndrome]
Lactose Intolerance
[Kallikrein and serotonin in the blood of patients with lactose intolerance]
Laryngeal Edema
Lanadelumab for the prevention of attacks in hereditary angioedema.
Leptospirosis
[The role of the kallikrein-kinin system in the pathogenesis of leptospirosis]
Leukemia
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Evaluation of viral and mammalian promoters for use in gene delivery to salivary glands.
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.
Studies on the components of the contact phase system in patients with acute nonlymphoblastic leukemia.
[Kininogenase activity of cathepsins D]
Leukemia, Lymphocytic, Chronic, B-Cell
KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia.
Plasma prekallikrein (Fletcher factor) deficiency in a patient with chronic lymphocytic leukemia.
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
Leukemia, Myeloid, Acute
Studies on the components of the contact phase system in patients with acute nonlymphoblastic leukemia.
Leukemia, Promyelocytic, Acute
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Leukocytosis
Failure of guinea pig plasma kallikrein to cause neutrophil migration.
Leukostasis
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
Purified human plasma kallikrein aggregates human blood neutrophils.
Liver Abscess
Plasma kallikrein elevation in cattle induced with hepatic abscess.
Liver Cirrhosis
Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites.
Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis.
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.
Interrelation between factor VII, prekallikrein, and hyperfibrinolysis in advanced cirrhosis.
L(59) TGF-? LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice.
LAP degradation product reflects plasma kallikrein-dependent TGF-? activation in patients with hepatic fibrosis.
Plasma prekallikrein and endotoxemia in liver cirrhosis.
Plasma prekallikrein levels in patients with hepatocellular carcinoma and liver cirrhosis: a pilot study.
Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay.
Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
[Behavior of the renin-angiotensin-aldosterone system and urinary kallikrein in patients with ascitic hepatic cirrhosis]
[Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis]
[Plasma prekallikrein in chronic liver diseases]
[Urinary kallikrein excretion in hepatic cirrhosis]
[Urinary kallikrein in acute hepatitis and liver cirrhosis]
Liver Cirrhosis, Alcoholic
Renal kallikrein excretion in alcoholic cirrhosis. Relationship to other vasoactive systems.
Liver Diseases
Chromogenic substrate assay of plasma prekallikrein. With a note on its site of biosynthesis.
Evaluation of a microassay for human plasma prekallikrein.
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.
Kinin activation in the blood of patients with sepsis.
Plasma prekallikrein and endotoxemia in liver cirrhosis.
Plasma prekallikrein as a prognostic indicator in chronic liver insufficiency.
Prekallikein and kallikrein inhibitor in liver cirrhosis and hepatitis.
Renal kallikrein excretion in alcoholic cirrhosis. Relationship to other vasoactive systems.
Renal kinin and kallikrein excretion in cirrhotic patients.
The kallikrein-kininogen-kinin system in patients with liver disease and ascites.
Urinary kallikrein excretion in chronic liver disease and effect of indomethacin.
Urinary kininogen: a possible regulator of kinin formation in normal individuals and subjects with essential hypertension, end-stage renal and liver disease.
[Plasma prekallikrein in chronic liver diseases]
Liver Failure
A novel chromogenic peptide for prekallikrein/kallikrein determination.
Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease.
Kinins, kininogen and kininogenase activity in pregnancy and hepatic failure.
Prekallikrein and factor VII as prognostic indexes of liver failure.
Screening coagulation tests and clotting factors in homozygous beta-thalassemia.
[Hepatic protein synthesis of the kallikrein-kininogen-kinin system]
Lung Injury
Plasma kallikrein contributes to ambient particulate matter-induced lung injury.
Lung Neoplasms
A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Biomarkers for the lung cancer diagnosis and their advances in proteomics.
Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation.
Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer.
Glycosaminoglycans and activated contact system in cancer patient plasmas.
Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer.
LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung.
Lupus Erythematosus, Systemic
Defective responsiveness to ascorbic acid of neutrophil random and chemotactic migration in Felty's syndrome and systemic lupus erythematosus.
Lupus Nephritis
Inducible expression of kallikrein in renal tubular cells protects mice against spontaneous lupus nephritis.
Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.
Kallikrein transduced mesenchymal stem cells protect against anti-GBM disease and lupus nephritis by ameliorating inflammation and oxidative stress.
Kallikreins and lupus nephritis.
Kinin system in lupus nephritis.
Lymphatic Metastasis
Decreased expression of kallikrein-related peptidase 13: Possible contribution to metastasis of human oral cancer.
Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.
Lymphoproliferative Disorders
Kallikrein system during treatment of hematological malignancies.
Macular Degeneration
The kallikrein system in retinal damage/protection.
Macular Edema
Central Retinal Vein Occlusion in 2 Patients Using Antipsychotic Drugs.
Diabetic Macular Edema: Current Understanding, Pharmacologic Treatment Options, and Developing Therapies.
Effects of kallidinogenase in patients undergoing vitrectomy for diabetic macular edema.
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study.
Oral kallidinogenase improved visual acuity and maintained chorioretinal blood flow levels after treatment for diabetic macular edema.
Plasma kallikrein and diabetic macular edema.
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema.
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.
Systemic exposure following intravitreal administration of therapeutic agents: an integrated pharmacokinetic approach. 1. THR-149.
Malaria
Kinins Released by Erythrocytic Stages of Plasmodium falciparum Enhance Adhesion of Infected Erythrocytes to Endothelial Cells and Increase Blood Brain Barrier Permeability via Activation of Bradykinin Receptors.
Soluble parasite antigens from Babesia canis do not directly activate the kallikrein system in dogs infected with Babesia canis.
Mania
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.
Mastitis
Altered plasma pharmacokinetics of ceftiofur hydrochloride in cows affected with severe clinical mastitis.
Mastocytosis
Stimulation of bone resorption in cultured mouse calvaria by Lys-bradykinin (kallidin), a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis.
Melanoma
[Changes in the proteolytic activity and components of the blood kallikrein-kinin system during the growth and metastasis of experimental neoplasms]
Meningococcal Infections
NHBA is processed by kallikrein from human saliva.
Mesothelioma
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation.
Metabolic Syndrome
Cardiovascular Biomarkers of Obesity and Overlap With Cardiometabolic Dysfunction.
Kallikrein-kinin system disbalance in chronic pancreatis in combination with metabolic syndrome.
Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.
Metrorrhagia
[The role of biologically active substances in the pathogenesis of dysfunctional uterine hemorrhage in the climacteric period]
Migraine Disorders
Arginine esterase in cerebrospinal fluid and pro-arginine esterase in plasma from patients with migraine.
Regulatory role of bradykinin in the coronary and cerebral circulations and in systemic hemodynamics.
Multiple Myeloma
Elevated extracellular trap formation and contact system activation in acute leukemia.
Kallikrein system during treatment of hematological malignancies.
Multiple Sclerosis
[Significance of kallikrein-kinin system in central nervous system diseases].
Muscular Dystrophies
Proteomic identification of elevated saliva kallikrein levels in the mdx-4cv mouse model of Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Dataset on the comparative proteomic profiling of mouse saliva and serum from wild type versus the dystrophic mdx-4cv mouse model of dystrophinopathy.
Proteomic identification of elevated saliva kallikrein levels in the mdx-4cv mouse model of Duchenne muscular dystrophy.
Myasthenia Gravis
Lupus anticoagulant in myasthenia gravis associated with IgM gammopathy.
Myelodysplastic Syndromes
Elevated extracellular trap formation and contact system activation in acute leukemia.
Myeloproliferative Disorders
Kallikrein system during treatment of hematological malignancies.
Myocardial Infarction
Antibody-array interaction mapping, a new method to detect protein complexes applied to the discovery and study of serum amyloid P interactions with kininogen in human plasma.
Antigen levels of coagulation factor XII, coagulation factor XI and prekallikrein, and the risk of myocardial infarction and ischemic stroke in young women.
Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients.
Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction.
Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction.
Changes in the plasma kinin system in patients with myocardial infarction.
Effect of aspirin on renal function and the prostaglandin-kallikrein systems early after myocardial infarction.
Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease.
Fletcher factor deficiency and myocardial infarction.
Genetic determinants of activity and antigen levels of contact system factors.
Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction.
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion.
Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction.
Kinin and myocardial infarction: effect of Trasylol on the plasma prekallikrein and kallikrein inhibitor.
Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report.
New perspective on the tissue kallikrein-kinin system in myocardial infarction: role of angiogenesis and cardiac regeneration.
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.
Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.
Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.
Tissue kallikrein infusion prevents cardiomyocyte apoptosis, inflammation and ventricular remodeling after myocardial infarction.
Urinary excretion of kallikrein following myocardial infarction.
[Activity of the kallikrein-kinin system in experimental myocardial infarct in dogs and the effect of catecholamines]
[Changes in the kallikrein-kinin system of the blood during development of experimental myocardial infarct]
[Dynamic changes of the plasma prekallikrein activity in patients with acute myocardial infarction]
[Enzyme dynamics of the quinine system in the acute phase of the myocardial infarct: levels of kallikreinogen and of the kallikrein inhibitor]
[Functional properties of thrombocytes and inhibitors of proteolytic enzymes of the blood in patients with acute forms of ischemic heart disease]
[Interrelation of the blood kallikrein-kinin and anticoagulation systems in experimental myocardial infarct]
[Kininogenase and kinase activity in myocardial infarction]
Myocardial Ischemia
Effect of the Kallikrein Inhibitor Aprotinin on Myocardial Ischemia and Necrosis in Man.
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion.
Observations on the plasma kallikrein system during myocardial ischemia.
The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.
[Changes in the serum level of prekallikrein and kallikrein inhibitor activity in ischemic heart disease]
[Kallikrein activation and kininogen level in rat venous and arterial blood in acute myocardial ischemia]
Myocarditis
[Diagnostic significance of indices of kininogenesis in infectious-allergic myocarditis]
Myotonic Dystrophy
Gene for progressive familial heart block type I maps to chromosome 19q13.
Predictive diagnosis of myotonic dystrophy with flanking microsatellite markers.
Myotoxicity
Transcriptome analysis of expressed sequence tags from the venom glands of the fish Thalassophryne nattereri.
Neoplasm Metastasis
Bikunin--not just a plasma proteinase inhibitor.
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors.
Decreased expression of kallikrein-related peptidase 13: Possible contribution to metastasis of human oral cancer.
Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.
Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis.
Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
Metastasis of ovarian cancer is mediated by kallikrein related peptidases.
Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.
The structural network of Interleukin-10 and its implications in inflammation and cancer.
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
[Changes in the proteolytic activity and components of the blood kallikrein-kinin system during the growth and metastasis of experimental neoplasms]
[Effect of kallikrein on lung metastasis of cancer cells, and its influence on platelet aggregation]
Neoplasm, Residual
Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Neoplasms
A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs.
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
A novel chromogenic peptide for prekallikrein/kallikrein determination.
A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.
A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors.
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness.
Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.
Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers.
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.
Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery.
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Application of machine learning to large in vitro databases to identify drug-cancer cell interactions: azithromycin and KLK6 mutation status.
Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery.
Bikunin--not just a plasma proteinase inhibitor.
Blocking the proliferation of human tumor cell lines by peptidase inhibitors from bauhinia seeds.
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Blood pressure, renin-angiotensin system and urinary kallikrein in a case of juxtaglomerular cell tumor.
Bradykinin and nitric oxide in infectious disease and cancer.
Characterisation of human kallikrein 6/protease M expression in ovarian cancer.
Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors.
Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer.
Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer.
Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies.
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo.
Copy number variants in the kallikrein gene cluster.
Crystallization and preliminary crystallographic studies of human kallikrein 7, a serine protease of the multigene kallikrein family.
Decreased expression of kallikrein-related peptidase 13: Possible contribution to metastasis of human oral cancer.
Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma.
Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma.
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers.
Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
Downregulation of KLK13 promotes the invasiveness and metastasis of oesophageal squamous cell carcinoma.
Early activation of bradykinin B2 receptor aggravates reactive oxygen species generation and renal damage in ischemia/reperfusion injury.
Effect of aprotinin on metastasis of Lewis lung tumor in mice.
Effect of aprotinin, EACA and heparin on growth and vasopeptide system of Murphy-Sturm lymphosarcoma.
Effect of focal irradiation on plasma kallikrein activity in tumor bearing rats.
Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Effects of a combined drug regimen on tumour necrosis factor and plasma kallikrein activity in experimental endotoxaemia.
Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.
Elevated extracellular trap formation and contact system activation in acute leukemia.
Emerging interest in the kallikrein gene family for understanding and diagnosing cancer.
Epigenetic activation of human kallikrein 13 enhances malignancy of lung adenocarcinoma by promoting N-cadherin expression and laminin degradation.
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Experimental model and immunohistochemical analyses of U87 human glioblastoma cell xenografts in immunosuppressed rat brains.
Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer.
Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma.
Factor XII blockade inhibits aortic dilatation in angiotensin II-infused apolipoprotein E-deficient mice.
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
Flushing in the carcinoid syndrome and plasma kallikrein.
Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4.
Heat Shock Protein 90 (Hsp90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.
Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker.
Human kallikrein 10, a predictive marker for breast cancer.
Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.
Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.
Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer.
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.
Human tissue kallikrein gene family: applications in cancer.
Human tissue kallikreins and testicular cancer.
Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions.
Human Tissue Kallikreins in Polymorphous Adenocarcinoma: A Polymerase Chain Reaction and Immunohistochemical Study.
Human tissue kallikreins: the cancer biomarker family.
Identification of human glandular kallikrein in the beta cell of the pancreas.
Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation.
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils.
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.
Immunohistochemical expression of kallikrein 7 in oral squamous cell carcinoma.
Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.
Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta.
In-silico analysis of kallikrein gene expression in pancreatic and colon cancers.
Increased plasma kallikrein activity and tumour growth suppression associated with intralesional bradykinin injections in hamsters.
Inflammatory changes in tumour vessels after systemic 5-hydroxytryptamine, bradykinin, kallikrein, or lysolecithin.
Inflammatory response to cardiopulmonary bypass.
Inhibition of carrageenan-induced expression of tissue and plasma prekallikreins mRNA by low level laser therapy in a rat paw edema model.
Inhibition of growth of 3-methylcholanthrene-induced mouse skin tumor by protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate.
Integrated genomic characterization of the kallikrein gene locus in cancer.
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
Intron retention: a common splicing event within the human kallikrein gene family.
Isolation of membrane-bound renal enzymes that metabolize kinins and angiotensins.
Kallikrein 12 downregulation reduces AGS gastric cancer cell proliferation and migration.
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Kallikrein and kinin receptor expression in inflammation and cancer.
Kallikrein gene downregulation in breast cancer.
Kallikrein gene family as biomarkers for recurrent prostate cancer.
Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas.
Kallikrein-related peptidase 13: an independent indicator of favorable prognosis for patients with nonsmall cell lung cancer.
Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer - A Pilot Study.
Kinin-generating cascade in advanced cancer patients and in vitro study.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
KLK6 Promotes Growth, Migration, and Invasion of Gastric Cancer Cells.
Levels of glandular kallikrein in whole saliva obtained from patients with solid tumors remote from the oral cavity.
Low molecular weight organic acids as inhibitors of kinin-forming activity of a rodent tumor acid protease and human plasma kallikrein.
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
Mechanisms of hepatocyte growth factor activation in cancer tissues.
Mining human cancer datasets for kallikrein expression in cancer: the 'KLK-CANMAP' Shiny web tool.
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery.
Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies.
Plasma kallistatin in critically ill patients with severe sepsis and septic shock.
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer.
Proliferation and differentiation of rat adipose precursor cells in chemically defined medium: differential action of anti-adipogenic agents.
Proteases during the growth of Ehrlich ascites tumor. II. The kallikrein-kinin system.
Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells.
Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung.
Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival.
Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.
Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Structural elements of kallistatin required for inhibition of angiogenesis.
Studies on components of the contact phase system in patients with advanced gastrointestinal cancer.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
The canine kallikrein-related peptidases 9 and 10: structural characterization and expression in mammary cancer.
The epigenetic basis for the aberrant expression of kallikreins in human cancers.
The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids.
The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models.
The kallikrein world: an update on the human tissue kallikreins.
The new human tissue kallikrein gene family: structure, function, and association to disease.
The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer.
The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family.
Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.
Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers.
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Trp(250) -hK2 is defective in intracellular trafficking and activates the unfolded protein response.
Tumor markers: an update on human kallikrein 2.
Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein.
Urinary kallikrein 10 predicts the incurability of gastric cancer.
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
[CASES OF CANCER OF VATER'S AMPULLA TREATED WITH KALLIKREIN AND TRYPSIN INACTIVATOR (TRASYLOL).]
[Changes in the proteolytic activity and components of the blood kallikrein-kinin system during the growth and metastasis of experimental neoplasms]
[Diagnostic relevance of saliva analysis in parotid tumors]
[Effect of kallikrein on lung metastasis of cancer cells, and its influence on platelet aggregation]
[ON THE EXCRETION OF KALLIKREIN INACTIVATOR AND ITS BEHAVIOR TOWARD TUMOR CELLS IN VIVO.]
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
[Renin secreting tumor and urinary excretion of kallikrein]
[Significance of kallikrein-kinin system in central nervous system diseases].
[Tumor markers of urinary tract carcinoma]
Neoplasms, Germ Cell and Embryonal
Human tissue kallikreins and testicular cancer.
Nephritis
Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans.
Kallikreins and lupus nephritis.
Nephritis blunts urinary kallikrein excretion and aggravates DOCA/NaCl hypertension in rats.
Participation of kallikrein, coagulation/fibrinolysis parameters in the development of glomerulonephritis.
Plasma activity of contact coagulation factors in patients with IgA nephritis.
Studies on mechanisms of antinephritic action of SA-446 an angiotensin I converting enzyme inhibitor (1). A comparison with actions of spironolactone, kallidinogenase and saralasin.
Urinary kallikrein in experimental renal disease.
[State of the kinin system and level of serum proteinase inhibitors in latent nephritis and the nephrotic syndrome of different etiology]
Nephrosclerosis
Linkage analysis between loci in the renin-angiotensin axis and end-stage renal disease in African Americans.
Nephrosis
Urinary kallikrein in experimental renal disease.
Nephrosis, Lipoid
Urine kallikrein excretion in relation to renal sodium handling in minimal change nephrotic syndrome.
Nephrotic Syndrome
A clinical study on urinary kallikrein in patients with renal diseases.
A study of the plasma kinin-generating system in children with the minimal lesion, idiopathic nephrotic syndrome.
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.
Mechanism and significance of kinin formation in nephrotic syndrome.
Role of proteases in hypercatabolic patients with renal failure.
The kallikrein-kinin and renin-angiotensin systems in nephrotic syndrome.
Urinary excretion of Hageman factor (factor XII) and the presence of nonfunctional Hageman factor in the nephrotic syndrome.
Urinary kallikrein excretion in glomerulonephritis and nephrotic syndrome.
Urinary kallikrein excretion in idiopathic nephrotic syndrome.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
Urine kallikrein excretion in relation to renal sodium handling in minimal change nephrotic syndrome.
[A substrate inhibitor analysis of the urinary excretion of tissue and plasma kallikreins in patients with chronic glomerulonephritis]
[Kallikrein excretion in patients with nephritic and nephrotic syndromes]
[Kinin system components, free kinins and proteinase inhibitors in the edematous fluids of nephrotic syndrome patients]
[State of the blood prekallikrein-kallikrein system in patients with glomerulonephritis as affected by pathogenetic therapy]
[State of the kinin system and level of serum proteinase inhibitors in latent nephritis and the nephrotic syndrome of different etiology]
[The participation of the kallikrein-kinin system in edema formation in glomerulonephritis]
[The role of biologically active substances in permeability changes in the blood vessels of patients with hemorrhagic fever with renal syndrome]
[Urinary kallikrein excretion in patients with nephrotic syndrome and evaluation of the anlytical methods]
[Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome]
Nervous System Diseases
The protein therapy of kallikrein in cerebral ischemic reperfusion injury.
Netherton Syndrome
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Treatment of ichthyosis and hypernatremia in a patient with Netherton syndrome with a SPINK5 c.153delT mutation using kallikrein inhibiting ointment.
Neuroblastoma
Identification of latent tissue kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmunoassays.
Neuroinflammatory Diseases
Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.
Neutropenia
Comparison of the cardiopulmonary responses to single bolus and continuous infusion of endotoxin in an ovine model.
Purified human plasma kallikrein aggregates human blood neutrophils.
Non-alcoholic Fatty Liver Disease
Theaflavin TF3 Relieves Hepatocyte Lipid Deposition through Activating an AMPK Signaling Pathway by targeting Plasma Kallikrein.
Obesity
Contact activated kallikrein generation is reduced six months after gastric bypass.
Oligospermia
Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting.
Effects of kallikrein on the male reproductive system and its use in the treatment of idiopathic oligozoospermia with impaired motility.
Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial.
Oral pentoxifylline in therapy-resistant idiopathic OAT syndrome.
Penetration capacity of spermatozoa from patients with oligoasthenoteratozoospermia into bovine cervical mucus before and after therapy with kallikrein.
Possible effects of the kallikrein-kinin system on male reproductive functions.
Potentialities and limitations of endocrine treatment in idiopathic oligozoospermia.
Tamoxifen and kallikrein in therapy of oligoasthenozoospermia: results of a randomized study.
The effect of kallikrein on human sperm membrane function.
The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia.
Treatment of idiopathic oligozoospermia by kallikrein: results of a double-blind study.
[Absorption of swine pancreatic kallikrein in humans]
[Andrological, biochemical and endocrinological studies of subfertile men during kallikrein therapy]
[First results of parenteral treatment of male fertility disorders using kallikrein: oligozoospermia]
[Kallikrein in a double-blind study in idiopathic oligozoospermia]
[Systemic therapy of male subfertility]
[The effect of kallikrein and caffeine on the sperm survival of cryopreserved semen in patients with oligozoospermia]
[Treatment of fertility disturbances in the male with a combination of mesterolone and kallikrein]
Oliguria
Association between renal and sympathetic responses to nonhypotensive systemic sepsis.
Urinary prostaglandins and kallikrein in the course of acute renal failure.
Osteoarthritis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis.
Kallikrein in synovial fluid with rheumatoid arthritis.
Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.
[Change in the blood kallikrein system in rheumatoid arthritis and deforming osteoarthrosis under the effect of radon baths and the action of decimeter vawes]
[Condition of the kallikrein, coagulation and fibrinolytic systems of the blood in patients with osteoarthrosis]
Osteoporosis
Stimulation of bone resorption in cultured mouse calvaria by Lys-bradykinin (kallidin), a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis.
Otitis Media
Significance of kallikrein-kinin system in otitis media with effusion.
Otitis Media with Effusion
Plasma component of middle ear effusion evaluated by prekallikrein level.
Significance of kallikrein-kinin system in otitis media with effusion.
Ovarian Neoplasms
A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.
Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.
Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins.
Characterisation of human kallikrein 6/protease M expression in ovarian cancer.
Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients.
Human kallikrein 13 involvement in extracellular matrix degradation.
Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer.
Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer.
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer.
Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis.
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
Kallikreins as Markers of Disseminated Tumour Cells in Ovarian Cancer - A Pilot Study.
Kallikreins, steroid hormones and ovarian cancer: is there a link?
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Metastasis of ovarian cancer is mediated by kallikrein related peptidases.
Ovarian cancer specific kallikrein profile in effusions.
Parallel overexpression of seven kallikrein genes in ovarian cancer.
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
Prognostic value of the human kallikrein gene 15 expression in ovarian cancer.
Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis.
Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker.
Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer.
The epigenetic basis for the aberrant expression of kallikreins in human cancers.
The human kallikrein gene family: new biomarkers for ovarian cancer.
The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer.
Pancreatic Diseases
Urinary kallikrein excretion in chronic pancreatic diseases.
Pancreatitis
Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
Antiproteasic activity of C1 inhibitor. Therapeutic perspectives.
Aprotinin in severe acute pancreatitis.
Biochemical characterization of reperfusion pancreatitis in porcine pancreatic allografts after six hours of cold storage.
Blood kallikrein. Kinin system in acute pancreatitis.
Changes in the kallikrein kinin system during acute pancreatitis in man.
Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma.
Direct radioimmunoassay of active and inactive human glandular kallikrein: some physiological and pathological variabilities.
Early phase components of the kallikrein kinin system in hemorrhagic ascitic fluid and plasma in the rat with induced acute pancreatitis.
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Inflammatory response in the initial phase of acute pancreatitis: relationship to the onset and severity of the disease.
Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy.
Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats.
Kallikrein inhibitors limit kinin B(2) antagonist-induced progression of oedematous to haemorrhagic pancreatitis in rats.
Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors.
Mechanism of kinin release during experimental acute pancreatitis in rats: evidence for pro- as well as anti-inflammatory roles of oedema formation.
Oleic acid induced pancreatitis in pigs.
Peritoneal lavage efficiently eliminates protease-alpha-2-macroglobulin complexes and components of the contact system from the peritoneal cavity in patients with severe acute pancreatitis.
Purification and characterization of kallikrein from plasma of patients with acute pancreatitis.
Role of the kallikrein-kinin system in human pancreatitis.
Studies on a kallikrein-kinin system in plasma of patients with acute pancreatitis: the preparation and characterization of a kallikrein-like enzyme in patient's plasma.
Studies on kallikrein-kinin system in plasma of patients with acute pancreatitis.
THE EFFECT OF A KALLIKREIN INACTIVATOR ON EXPERIMENTAL ACUTE PANCREATITIS.
Urinary kallikrein excretion in chronic pancreatic diseases.
[A prognostic criterion for the course of chronic recurrent pancreatitis]
[Acute pancreatitis and kallikrein inactivator. (Experimental study)]
[Behavior of urinary kallikrein during acute pancreatitis. Personal studies]
[Changes in some of the kallikrein-kinin system indices in patients with acute pancreatitis]
[Effect of trypsin and kallikrein (andecalin) on the activity of proteolytic enzymes and their inhibitors in acute experimental pancreatitis]
[Effects of trypsin and kallikrein inhibition in acute pancreatitis]
[Enzyme liberation and activation of the kallikrein-kinin system in experimental pancreatitis. Studies of portal vein blood, pancreatic lymph and peritoneal effusion]
[Interaction of proteases and their inhibitors in the pathogenesis of pancreatitis]
[Kininogenase and kininogen in blood plasma of patients with acute pancreatitis]
[Pancreatitis therapy with a kallikrein inactivator.]
[Preliminary experiences with the kallikrein inactivator "trasylol" in acute pancreatitis.]
[ROLE OF TRASYLOL--TRYPSIN INACTIVATOR--AND KALLIKREIN IN PANCREATITIS.]
[Therapy with kallikrein and trypsin inhibitors, a part of the modern treatment of acute pancreatitis.]
[Treatment of a case of acute pancreatitis using a local perfusion of kallikrein inhibitors]
Pancreatitis, Acute Necrotizing
[Cure of acute traumatic pancreatic necrosis with the kallikrein inactivator Trasylol.]
Pancreatitis, Chronic
combination effect of hypertonic disease with chronic pancreatitis on the processes maintain homeostasis.
Determination of kallikrein by radioimmunoassay in human body fluids.
Kallikrein-kinin system disbalance in chronic pancreatis in combination with metabolic syndrome.
Role of the kallikrein-kinin system in human pancreatitis.
Papilledema
Effects of kallidinogenase on retinal edema and size of non-perfused areas in mice with retinal vein occlusion.
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.
Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy.
The kallikrein/kinin system in ocular function.
Paraparesis, Spastic
[Therapeutic use of padutin with special reference to depot padutin in spastic paraparesis.]
Parasitic Diseases
Kinins Released by Erythrocytic Stages of Plasmodium falciparum Enhance Adhesion of Infected Erythrocytes to Endothelial Cells and Increase Blood Brain Barrier Permeability via Activation of Bradykinin Receptors.
Parotid Diseases
New concepts in the treatment of chronic recurrent parotitis.
Parotitis
New concepts in the treatment of chronic recurrent parotitis.
Salivary factors in children with recurrent parotitis. Part 2: Protein, albumin, amylase, IgA, lactoferrin lysozyme and kallikrein concentrations.
[Glandular kallikrein in chronic recurrent parotitis]
[Treatment of chronic recurring parotitis with the protease inhibitor aprotinin (trasylol)]
Peptic Ulcer
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
[Mechanism of activation of the kallikrein-kinin system in human plasma in stomach and duodenal ulcer]
Periodontal Diseases
[Glandular and plasma kallikrein activities in saliva from patients with periodontal diseases]
[Kallikrein and kininase activities in whole saliva from patients with periodontal disease (author's transl)]
[Method for selective determination of kininogenase and kininase activities in saliva-serum reaction and the role of kinins in periodontal diseases]
[Role of salivary kallikrein in the pathogenesis of periodontosis]
Periodontitis
Salivary collagenase. Origin, characteristics and relationship to periodontal health.
Peripheral Nervous System Diseases
The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes.
Peripheral Vascular Diseases
Beneficial effects of a serine protease inhibitor in peripheral vascular disease.
Kallikrein in peripheral vascular disease.
[FIRST EXPERIENCES ON THE THERAPEUTIC ACTIVITY OF M-INOSITOL HEXANICOTINATE AND KALLIKREIN IN PERIPHERAL VASCULAR DISEASES AND IN CORONARY DISEASE.]
[Treatment of various peripheral vascular diseases with Padutin.]
Peritonitis
[Effect of kallikrein and its inhibitor on absorption from the abdominal cavity in peritonitis]
[Effect of kallikrein and its inhibitor on NA-125I absorption from the peritoneal cavity in acute peritonitis]
Pheochromocytoma
Excretion of human urinary kallikrein quantity measured by a direct radioimmunoassay of human urinary kallikrein in patients with essential hypertension and secondary hypertensive diseases.
Pituitary ACTH Hypersecretion
Dissociation between kallikrein and aldosterone in Cushing's disease with periodic hormonogenesis.
Pituitary Neoplasms
Kallikrein gene expression in estrogen-induced pituitary tumors.
Kallikrein gene expression in human pituitary tissues.
The control by estradiol of pituitary tumor and cell growth is not correlated with that of kallikrein gene expression.
Placenta Accreta
Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric oxide synthase in placenta in normal gestation, preeclampsia, and placenta accreta.
plasma kallikrein deficiency
A Case of Prekallikrein Deficiency Resulting in Severe Recurrent Mucosal Hemorrhage.
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
A hitherto undescribed plasma factor acting at the contact phase of blood coagulation (Flaujeac factor): case report and coagulation studies.
A large family from Argentina with prekallikrein deficiency due to a compound heterozygosis (T insertion in intron 7 and Asp558Glu in exon 15): prekallikrein Cordoba.
A new family with congenital factor XII deficiency.
A new Italian family with severe prekallikrein deficiency. Desmopressin-induced fibrinolysis and coagulation changes in homozygous and heterozygous members.
A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region.
A Rare Cause of Isolated Prolonged Activated Partial Thromboplastin Time: An Overview of Prekallikrein Deficiency and the Contact System.
A structure-function analysis in patients with prekallikrein deficiency.
Activated partial thromboplastin time and minor coagulopathies.
An acquired prekallikrein deficiency can be diagnosed only after a sure exclusion of a congenital condition.
Antithrombotic potential of the contact activation pathway.
Automated APTT cycle for the rapid identification of plasma prekallikrein deficiency.
c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans.
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.
Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency.
Combined occurrence of Bernard-Soulier syndrome and prekallikrein deficiency.
Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.
Complete prekallikrein deficiency masquerading as a lupus anticoagulant.
Congenital prekallikrein deficiency.
CRM+ severe Fletcher factor deficiency associated with Graves' disease.
Deficiency of fibrinolytic enzyme activities in the serum of patients with Alzheimer-type dementia.
Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease.
Diagnostic Pearls and Clinical Implications of Prekallikrein Deficiency.
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait.
Evidence against collagen activation of platelet-associated factor XI as a mechanism for initiating intrinsic clotting.
Factor XII and partial prekallikrein deficiencies in a dog with recurrent gastrointestinal hemorrhage.
Fletcher factor deficiency (Report of a new case).
Fletcher factor deficiency and myocardial infarction.
Fletcher factor deficiency in a 9-year-old girl: mechanisms of the contact pathway of blood coagulation.
Fletcher factor deficiency in a woman requiring emergency caesarean section.
Fletcher factor deficiency with mildly prolonged activated PTT.
Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test.
Fletcher factor deficiency--detection of a severe case in a population survey.
Fletcher Factor Deficiency.
Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.
Fletcher factor deficiency: a report of three unrelated cases.
Fletcher factor deficiency: family study and detection.
Fletcher factor deficiency: report of a new family.
Genetics of equine bleeding disorders.
Heterogeneity of human prekallikrein deficiency (Fletcher trait): evidence that five of 18 cases are positive for cross-reacting material.
HLA typing in a new family with Fletcher factor deficiency.
Homozygous Prekallikrein Deficiency in the USA: Several Patients but Still Few Mutation Studies.
Human plasma kallikrein-kinin system: physiological and biochemical parameters.
Increased Prevalence of Reported Cases of Congenital Prekallikrein Deficiency Among African Americans as Compared With the General Population of the United States.
Isolated prolonged activated partial thromboplastin time in an asymptomatic patient: Fletcher factor deficiency.
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency.
Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
Long-term safety outcomes of prekillikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency.
Management of prekallikrein deficiency during cardiac surgery.
Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report.
Pathophysiology of thrombophilic states.
Plasma prekallikrein (Fletcher factor) deficiency in a patient with chronic lymphocytic leukemia.
Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay.
Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.
Prekallikrein (Fletcher factor) deficiency.
Prekallikrein deficiency in a 15-year-old boy with Ménière's disease: a case report.
Prekallikrein deficiency in a dog.
Prekallikrein Deficiency in a Dog.
Prekallikrein deficiency in a family of Belgian horses.
Prekallikrein deficiency in a family of miniature horses.
Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma.
Prekallikrein deficiency in man.
Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.
Prekallikrein deficiency.
Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII.
Prevalence of Cardiovascular Disorders in African-Americans With Congenital Prekallikrein Deficiency Versus Caucasians-Americans With the Same Defect.
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
Prolonged Activated Clotting Time Immediately Prior to Open Cardiac Surgery.
Prolonged activated partial thromboplastin time due to plasma prekallikrein deficiency: a case study and literature review on its clinical significance.
Prolonged activated partial thromboplastin time with no clear explanation.
Prolonged Partial Thromboplastin Time Without Bleeding History; Fletcher Factor Deficiency.
Replacement therapy in a patient with congenital prekallikrein deficiency undergoing surgery.
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Role of plasma kallikrein in diabetes and metabolism.
Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence.
Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr).
Severe prekallikrein deficiencies due to homozygous C529Y mutations.
Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation.
Severe Prekallikrein Deficiency Associated with Low Level of Factor XII: A Case Report.
Severe prekallikrein deficiency due to a compound heterozygosis in the KLKB1-gene.
Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation.
Spinal anesthesia in a patient with prekallikrein deficiency.
Stroke in a young adult with Fletcher trait.
Studies of the renal vasoactive systems in hyporeninemic hypoaldosteronism.
The effect of increased contact activation time on the activated partial thromboplastin time.
The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c.1198G>T).
The old and the new in prekallikrein deficiency: historical context and a family from Argentina with PK deficiency due to a new mutation (Arg541Gln) in exon 14 associated with a common polymorphysm (Asn124Ser) in exon 5.
Thrombotic Events in Patients with Congenital Prekallikrein Deficiency: A Critical Evaluation of All Reported Cases.
Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency.
[An elderly case of congenital prekallikrein deficiency]
[Isolated prolongation of the PTT: 2-year retrospective study]
[Plasma prekallikrein deficiency in a strain of Brown Norway rats]
[Plasma prekallikrein deficiency: 1st case diagnosed in Brazil]
[Prekallikrein deficiency (Fletcher trait)]
[Prekallikrein deficiency: a rare cause of a significant prolongation of the activated partial thromboplastin time. Apropos of a case]
[Prekallikrein deficiency: apropos of 2 cases]
[Use of chromogenic substrates in the clarification of disorders in the early stages of blood coagulation]
Pleurisy
Activation of plasma kallikrein-kinin system and its significant role in pleural fluid accumulation of rat carrageenin-induced pleurisy.
Assay methods for prekallikrein and kininogens and their applications.
Different modes of interaction of bradykinin with prostaglandins in pain and acute inflammation.
Effects of an orally active non-peptide bradykinin B2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin-induced pleurisy.
Modulation of plasma exudation by PGE2 and that of leukocyte migration by LTB4 in inflammatory models.
Role of high molecular weight (HMW)-kininogen in inflammatory exudation: evidence with the studies of the HMW-kininogen deficient rat.
[The antiinflammatory effect of EB-382]
Pneumonia
Fine particulate matter increases airway hyperresponsiveness through kallikrein-bradykinin pathway.
Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis.
The Plant-Derived Bauhinia bauhinioides Kallikrein Proteinase Inhibitor (rBbKI) Attenuates Elastase-Induced Emphysema in Mice.
Polycystic Kidney Diseases
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Polycythemia
Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia.
Polyuria
Effects of aldosterone and deoxycorticosterone on the urniary excretion of kallikrein and of prostaglandin E-like substance in the rat.
[Significance of kallikrein, angiotensin-converting enzyme, and proteolysis inhibitors in vascular complications in diabetes mellitus type 1 in children]
Post-Exercise Hypotension
Effect of type 2 diabetes on plasma kallikrein activity after physical exercise and its relationship to post-exercise hypotension.
Increase in kinins on post-exercise hypotension in normotensive and hypertensive volunteers.
Kallikrein kinin system activation in post-exercise hypotension in water running of hypertensive volunteers.
Type 2 diabetes elicits lower nitric oxide, bradykinin concentration and kallikrein activity together with higher DesArg(9)-BK and reduced post-exercise hypotension compared to non-diabetic condition.
Pre-Eclampsia
A comparison of the inactive urinary kallikrein: creatinine ratio and the angiotensin sensitivity test for the prediction of pre-eclampsia.
A comparison of the inactive urinary kallikrein:creatinine ratio and the angiotensin sensitivity test for the prediction of pre-eclampsia.
Circulating levels of prekallikrein and kallikrein in pregnancy and labor.
Early prediction of pre-eclampsia by measurement of kallikrein and creatinine on a random urine sample.
Expression of kallikrein, bradykinin b2 receptor, and endothelial nitric oxide synthase in placenta in normal gestation, preeclampsia, and placenta accreta.
Prostacyclin-like, and kallikrein activity of amniotic fluid in pre-eclampsia.
The kinin-forming enzyme system in pregnancy and obstetrical DIC.
Urinary coagulation-fibrinolysis, kallirein-kinin systems and kininase in cases of preclampsia.
Urinary kallikrein excretion in normal and hypertensive pregnancy at term.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
World Health Organization systematic review of screening tests for preeclampsia.
[Plasma prekallikrein level in pregnancy toxemia]
Primary Graft Dysfunction
Plasma kallikrein predicts primary graft dysfunction after heart transplant.
Primary Myelofibrosis
Prevalence of hypertension and its complications in congenital prekallikrein deficiency: analysis of all reported cases and clinical significance.
Prion Diseases
Biological network inferences for a protection mechanism against familial Creutzfeldt-Jakob disease with E200K pathogenic mutation.
Prolactinoma
Characterization of a tissue kallikrein in human prolactin-secreting adenomas.
Kallikrein gene expression in human pituitary tissues.
Prostatic Diseases
Modulation of recombinant human prostate-specific antigen: activation by Hofmeister salts and inhibition by azapeptides. Appendix: thermodynamic interpretation of the activation by concentrated salts.
Prostatic Hyperplasia
Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]
[THE ROLE OF KALLIKREIN-KININ AND RENIN- ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF PROSTATE CANCER].
Prostatic Neoplasms
4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
A Four-kallikrein Panel and ?-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Prostate Cancer Screening, Rotterdam.
A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates.
A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.
A novel transcript from the KLKP1 gene is androgen regulated, down-regulated during prostate cancer progression and encodes the first non-serine protease identified from the human kallikrein gene locus.
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy.
ANNALS EXPRESS: Frequency of KLK3 gene deletions in the general population.
Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.
Biomarkers for prostate cancer detection.
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity.
Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA.
Design of new and sensitive fluorogenic substrates for human kallikrein hK3 (prostate-specific antigen) derived from semenogelin sequences.
Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry.
Development of sensitive immunoassays for free and total human glandular kallikrein 2.
Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer.
Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and Regulation by multiple hormones.
Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
Editorial for "Diagnostic Performance of Prostate MRI Radiomics, Four Kallikrein Panel and Radiologist in the Detection of Prostate Cancer: A Retrospective External Validation Multi-center Study of Men With a Clinical Suspicion of Prostate Cancer".
Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
Emerging PSA-Based Tests to Improve Screening.
Epithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.
Ethnic variation in kallikrein expression in nipple aspirate fluid.
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Evidence that the prostate-specific antigen (PSA)/Zn2+ axis may play a role in human prostate cancer cell invasion.
Expanded human tissue kallikrein family--a novel panel of cancer biomarkers.
Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis.
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.
Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation.
Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.
Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues.
Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression.
Human tissue kallikrein gene family: a rich source of novel disease biomarkers.
Human tissue kallikrein gene family: applications in cancer.
Human tissue Kallikreins: Blood levels and response to radiotherapy in intermediate risk prostate cancer.
Human tissue kallikreins: the cancer biomarker family.
Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue.
Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Individual patient data meta-analysis of discrimination of the four kallikrein panel associated with the inclusion of prostate volume.
Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid.
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
Kallikrein gene family as biomarkers for recurrent prostate cancer.
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.
Kallikreins as biomarkers for prostate cancer.
Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus.
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.
MicroRNA-3162-5p-Mediated Crosstalk between Kallikrein Family Members Including Prostate-Specific Antigen in Prostate Cancer.
Molecular and reconstructive urology: a coming together.
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer.
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Other biomarkers for detecting prostate cancer.
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics.
Precursor Isoform of Prostate-Specific Antigen and Human Kallikrein 2: Two New Promising Biomarkers for the Unsolved Challenge of Early Prostate Cancer Detection.
Predicting high risk disease using serum and DNA biomarkers.
Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam.
Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.
Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Prospective validation of microseminoprotein-? added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort.
Prostate-specific antigen and acute myocardial infarction: A possible new intriguing scenario.
Prostate-specific antigen and new related markers for prostate cancer.
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity.
Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system.
Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Prostate-specific antigen, prostate cancer, and disorders of hemostasis.
Prostate-specific antigen: what's new in 1997.
Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer.
Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator.
Quantitative analysis of kallikrein 15 gene expression in prostate tissue.
Re: Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-Specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.
Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival.
Simple purification procedure for human prostatic kallikrein hK2 in its active form.
SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?
Standardization of two immunoassays for human glandular kallikrein 2.
Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology.
Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.
The impaired viability of prostate cancer cell lines by the recombinant plant kallikrein inhibitor.
The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
The Kallikrein Panel for prostate cancer screening: its economic impact.
The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers.
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
Trp(250) -hK2 is defective in intracellular trafficking and activates the unfolded protein response.
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.
Very low PSA concentrations and deletions of the KLK3 gene.
[Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
[Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]
[New progress in precision diagnosis of prostate cancer].
[PSA and hK2 in the diagnosis of prostate cancer]
[The PSA gene: value in detection of circulating prostate cancer cells]
[THE ROLE OF KALLIKREIN-KININ AND RENIN- ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF PROSTATE CANCER].
Proteinuria
A comparative study of the measurement of urinary kallikrein by various methods in patients with essential hypertension and patients with proteinuria.
A study of the plasma kinin-generating system in children with the minimal lesion, idiopathic nephrotic syndrome.
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Contrasting effects of early and late orchiectomy on hypertension and renal disease in fawn-hooded rats.
Developmental patterns of blood pressure and urinary protein, kallikrein, and prostaglandin E2 in Dahl salt-hypertension-susceptible rats.
Early detection of the nephrotoxic effects of industrial chemicals: state of the art and future prospects.
Effects of aprotinin on the kallikrein-kinin system in type I diabetes (insulitis).
Exercise proteinuria and proteinuria induced by kallikrein.
Inactivation of urinary kallikrein by alpha 1-antitrypsin.
Kallikrein gene transfer reduces renal fibrosis, hypertrophy, and proliferation in DOCA-salt hypertensive rats.
Nephritis blunts urinary kallikrein excretion and aggravates DOCA/NaCl hypertension in rats.
Renal alteration and development of hypertension in diabetic rats.
Renal mechanisms in the cardiovascular effects of chronic exposure to inorganic mercury in rats.
Renal morphological changes after sinoaortic denervation in dogs.
Total and kallikrein arginine esterase activities in the urine of salt-hypertensive susceptible and resistant rats.
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Urinary kallikrein in experimental renal disease.
Urinary serine proteases and activation of ENaC in kidney-implications for physiological renal salt handling and hypertensive disorders with albuminuria.
[The participation of the kallikrein-kinin system in edema formation in glomerulonephritis]
Pruritus
Proteolytic activity in development of pain and itching. Cutaneous reactions to bradykinin and kallikrein.
Scratch induction in the rat by intradermal serotonin: a model for pruritus.
Psoriasis
Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.
Crystallization and preliminary crystallographic studies of human kallikrein 7, a serine protease of the multigene kallikrein family.
Decreased cutaneous reactions to kallikrein in patients with atopic dermatitis and psoriasis.
Evaluation of different treatment methods in patients with psoriasis and content of kallikrein and kallikreinogen in blood plasma.
Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins.
Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases.
Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
[Plasma levels of kallikrein and kallikreinogen and evaluation of different methods of treating psoriasis]
Pulmonary Disease, Chronic Obstructive
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
[Anticoagulants and changes in the coagulation status of patients with chronic obstructive lung disease and various degrees of respiratory failure]
Pulmonary Embolism
Association between KLKB1 Polymorphisms and Pulmonary Thromboembolism.
The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.
Purpura
[An elderly case of congenital prekallikrein deficiency]
Purpura, Thrombocytopenic, Idiopathic
Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation.
Pyelonephritis
[Kallikrein, nonspecific proteases and trypsin inhibitor in the urine of patients with pyelonephritis]
Pyometra
The plasma proteome and the acute phase protein response in canine pyometra.
Renal Artery Obstruction
A case of secondary aldosteronism similar to Bartter's syndrome with no abnormality in renal chloride reabsorption.
Renal venous output of kinins in patients with hypertension and unilateral renal artery stenosis.
[Status of the kallikrein and kinin systems of the blood in renal artery stenosis (experimental study)]
Renal Insufficiency
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics.
Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure.
Effect of magnesium lithospermate B on the renal and urinary kallikrein activities in rats with adenine-induced renal failure.
Enhanced parotid kallikrein secretion in essential, adrenal, and renoparenchymal hypertension and in advanced renal failure.
Magnesium lithospermate B improves renal function via the kallikrein-prostaglandin system in rats with renal failure.
Mild renal failure induced by subchronic exposure to molybdenum: urinary kallikrein excretion as a marker of distal tubular effect.
Natriuretic and smooth muscle responses to human urinary natriuretic hormone in rats: relation to blood pressure and kallikrein excretion in patients.
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics.
Renal Insufficiency, Chronic
Urinary kallikrein excretion in chronic renal disease with respect to salt intake and renal reserve.
Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Reperfusion Injury
Effect of kallikrein on microcirculation of rats with pancreatic ischemia reperfusion injury (IRI).
Human urine kininogenase attenuates balloon-induced intimal hyperplasia in rabbit carotid artery through transforming growth factor ?1/Smad2/3 signaling pathway.
Selective inhibition of plasma kallikrein protects brain from reperfusion injury.
The protein therapy of kallikrein in cerebral ischemic reperfusion injury.
Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Reproductive Tract Infections
Kallikrein and antibiotics in the treatment of infertile men with genital tract infections.
Respiratory Distress Syndrome
Activation of the kallikrein-kinin system in premature infants with respiratory distress syndrome (RDS).
Fibrinolysis inhibition in acute respiratory distress syndrome.
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
Prekallikrein activation in the adult respiratory distress syndrome.
Respiratory Insufficiency
[Gas exchange, microcirculation and blood kinins in patients with chronic nonspecific lung diseases]
Respiratory Tract Infections
[Effect of leukocyte interferon and its inducers on the prekallikrein-kallikrein system of the blood serum in children with acute respiratory viral infections]
Retinal Hemorrhage
The Effects of the Contact Activation System on Hemorrhage.
Retinal Perforations
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
Retinal Vein Occlusion
Effects of kallidinogenase on retinal edema and size of non-perfused areas in mice with retinal vein occlusion.
Rhinitis, Allergic
Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions.
Reduction by a kallikrein inhibitor of the increased nasal airway resistance of allergic patients after antigen challenge.
[Kinins and kallikrein in nasal secretion after antigen challenge in patients with allergic rhinitis]
Rocky Mountain Spotted Fever
Activation of the kallikrein-kinin system in Rocky Mountain spotted fever.
Rosacea
Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations in Rosacea and How Individual Treatments May Provide Therapeutic Benefit.
Sarcoidosis
Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease.
Sarcoma, Avian
Evaluation of viral and mammalian promoters for use in gene delivery to salivary glands.
Kallikrein gene therapy: a new strategy for hypertensive diseases.
Schistosomiasis
Prealbumin, prekallikrein and prothrombin in hepatosplenic schistosomiasis: increased turnover of the clotting proteins?
Scleroderma, Diffuse
Renal vasoactive hormones in scleroderma (progressive systemic sclerosis).
Seizures
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
Plasma kallikrein-kinin system contributes to peripheral inflammation in temporal lobe epilepsy.
The effect of kallikrein on central effects of acetylcholine in rats receiving indomethacin and prostaglandin E1.
[Effects of kallikrein and periston on hypoglycemic convulsions in mice.]
Sepsis
Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.
Acute renal failure and sepsis: therapeutic approaches.
Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery.
Association between renal and sympathetic responses to nonhypotensive systemic sepsis.
Bradykinin and nitric oxide in infectious disease and cancer.
Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.
Coagulation, fibrinolytic and kallikrein systems in neonates with uncomplicated sepsis and septic shock.
Complement C1 esterase inhibitor levels linked to infections and contaminated heparin-associated adverse events.
Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein.
Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats.
Evaluation of potential early markers of chorioamnionitis associated with preterm premature ruptured membranes.
Evaluation of severity and prognosis in early stages of septicemia by means of chromogenic peptide substrate assays.
Factor XII activation and inhibition in inflammation.
Fibrinolysis inhibition in acute respiratory distress syndrome.
Functional kallikrein inhibition during sepsis and bacterial shock.
Hemodynamic, renal, and hormonal actions of aprotinin in an ovine model of septic shock.
Inhibition of factor XI activation attenuates inflammation and coagulopathy while improving the survival of mouse polymicrobial sepsis.
Kallikrein, kininogen and kinins in control of blood pressure.
Kinin activation in the blood of patients with sepsis.
Kininogen supports inflammation and bacterial spreading during Streptococccus Pyogenes Sepsis.
Plasma kallikrein-kinin system in septicemia.
Regulation of angiogenesis by the kallikrein-kinin system.
Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients.
Studies on pathological plasma proteolysis in patients with septicemia.
The contact system proteases play disparate roles in streptococcal sepsis.
The functional inhibition of plasma kallikrein. A critical factor in septic shock.
The kallikrein-kinin system in the acutely-ill: (A) changes in plasma kininogen in acutely-ill patients. (B) the efficacy of pulmonary clearance of bradykinin.
Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays.
Uncontrolled plasma proteolysis: a major threat to the septicemic patient.
Severe Acute Respiratory Syndrome
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
Severe Dengue
Evaluation of the plasma kinin system in dengue hemorrhagic fever.
Shock, Septic
Changes in plasma levels of prekallikrein, kallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs.
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Coagulation, fibrinolytic and kallikrein systems in neonates with uncomplicated sepsis and septic shock.
Discovery of highly potent small molecule kallikrein inhibitors.
Falls in plasma levels of prekallikrein, high molecular weight kininogen, and kallikrein inhibitors during lethal endotoxin shock in dogs.
Identification of lipopolysaccharide binding site on high molecular weight kininogen.
Induction of vascular leakage and blood pressure lowering through kinin release by a serine proteinase from Aeromonas sobria.
Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock.
Plasma kallikrein activity and prekallikrein levels during endotoxin shock in dogs.
Plasma kallikrein localisation in human blood vessels.
Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock.
Plasma kallikrein-kinin system in septicemia.
Septic shock in the rat: activation of plasma proteolytic systems and effects of a kallikrein inhibitor/bradykinin antagonist (S-2441).
Studies of components of the coagulation systems in normal individuals and septic shock patients.
Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock.
Studies on pathological plasma proteolysis in patients with septicemia.
The effects of aprotinin on the phagocytic activity of the reticuloendothelial system and plasma prekallikrein levels during endotoxin shock.
The functional inhibition of plasma kallikrein. A critical factor in septic shock.
Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays.
Uncontrolled plasma proteolysis: a major threat to the septicemic patient.
[The effect of the protease inhibitor FUT-175 on phospholipase A2, complement, prostaglandins and prekallikrein during endotoxin shock]
Sialadenitis
Salivary kallikrein in Sjögren's syndrome.
Sjogren's Syndrome
Elevated Immunoglobulin to Tissue KLK11 in Patients With Sjögren Syndrome.
Skin Diseases
Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses.
Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation.
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Spinal Cord Injuries
Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.
Spotted Fever Group Rickettsiosis
Activation of the kallikrein-kinin system in Rocky Mountain spotted fever.
Squamous Cell Carcinoma of Head and Neck
[Quantitative studies of the kallikrein-prokallikrein system in mixed saliva in oral squamous epithelial carcinoma]
ST Elevation Myocardial Infarction
Associations of ACE I/D polymorphism with the levels of ACE, kallikrein, angiotensin II and interleukin-6 in STEMI patients.
Stomach Diseases
[Kallikrein as a stimulator of the acid-forming gland reserve in stomach diseases]
Stomach Neoplasms
Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas.
Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer.
The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents.
Urinary kallikrein 10 predicts the incurability of gastric cancer.
Stroke
Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation.
Exogenous kallikrein enhances neurogenesis and angiogenesis in the subventricular zone and the peri-infarction region and improves neurological function after focal cortical infarction in hypertensive rats.
Experimental therapy with tissue kallikrein against cerebral ischemia.
Human Tissue Kallikrein Promoted Activation of the Ipsilesional Sensorimotor Cortex after Acute Cerebral Infarction.
Ischemic stroke and traumatic brain injury: the role of the kallikrein-kinin system.
Kallikrein Protects Against Ischemic Stroke by Inhibiting Apoptosis and Inflammation and Promoting Angiogenesis and Neurogenesis.
Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis.
N-Butylphthalide vs. Human Urinary Kallidinogenase for the Treatment of Acute Ischemic Stroke: Functional Outcome and Impact on Serum VEGF and TNF-? Expressions.
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.
Reciprocal congenic lines for a major stroke QTL on rat chromosome 1.
Role of the kallikrein-kinin system in traumatic brain injury.
Stroke: kallikrein promotes hematoma expansion.
Study on the clinical efficacy of Human Urinary Kalllikrein in the treatment of acute cerebral infarction according to TOAST classification.
The renal kallikrein-kinin system in spontaneously hypertensive rats.
Ultrasound-Mediated Kallidinogenase-Loaded Microbubble Targeted Therapy for Acute Cerebral Infarction.
[Blood kallikrein-kinin system in ischemic stroke patients]
Synovitis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Kinins--key mediators in inflammatory arthritis?
Telangiectasia, Hereditary Hemorrhagic
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Telangiectasis
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Temporomandibular Joint Disorders
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Testicular Neoplasms
Human tissue kallikreins and testicular cancer.
Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer.
Tetanus
Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production.
Thalassemia
Interspliced transcription chimeras: neglected pathological mechanism infiltrating gene accession queries?
Thrombasthenia
Clinical and laboratorial description of the differential diagnoses of hemostatic disorders in the horse.
Genetics of equine bleeding disorders.
Thromboangiitis Obliterans
Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans.
Thromboinflammation
Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation.
Kininogen supports inflammation and bacterial spreading during Streptococccus Pyogenes Sepsis.
The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.
Thrombosis
A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris.
Antithrombotic potential of the contact activation pathway.
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation.
Contact activation of kallikrein-kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo.
Decrease of plasma prekallikrein and kallikrein inhibitors during intravenous phlebography.
Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection.
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait.
Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
Genetic variants associated with deep vein thrombosis: the F11 locus.
Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors.
Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor.
Kinins and thrombolysis.
Kinins Released by Erythrocytic Stages of Plasmodium falciparum Enhance Adhesion of Infected Erythrocytes to Endothelial Cells and Increase Blood Brain Barrier Permeability via Activation of Bradykinin Receptors.
Pathophysiology of thrombophilic states.
Physiologic activities of the contact activation system.
Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.
Plasma Kallikrein Inhibitors in Cardiovascular Disease: An Innovative Therapeutic Approach.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Plasma Kallikrein Structure Reveals Apple Domain Disc Rotated Conformation Compared to Factor XI.
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease.
Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis.
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis.
Role of plasma kallikrein in diabetes and metabolism.
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.
The concept and classification of antiphospholipid/cofactor syndromes.
The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models.
Thrombotic Events in Patients with Congenital Prekallikrein Deficiency: A Critical Evaluation of All Reported Cases.
von Willebrand Factor and Prekallikrein in Plasma Are Associated With Thrombus Volume in Abdominal Aortic Aneurysms.
[The role of anticardiolipin antibodies in the pathogenesis of arterial and venous thromboses]
Thrombotic Stroke
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Thyroid Neoplasms
Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.
Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer: a novel molecular marker?
Thyrotoxicosis
[Several aspects of the pathogenesis of disturbances of hemostasis in patients with diffuse toxic goiter]
Toxemia
Circulating levels of prekallikrein and kallikrein in pregnancy and labor.
Coagulation, fibrinolysis, platelet and kinin-forming systems during toxemia of pregnancy.
Coagulation-fibrinolytic and kinin-forming systems in toxemia of pregnancy.
The kinin-forming enzyme system in pregnancy and obstetrical DIC.
Urinary kallikrein in normal pregnancy, pregnancy with hypertension, and toxemia.
[Coagulation-fibrinolysis and kinin-forming systems in toxemia of pregnancy]
[Effect of pancreatic kallikrein and trypsin inhibitors on the course of postischemic toxemia]
[Effect of proteolysis inhibitors on serum proteinase activity and its antitryptic activity in postischemic toxemia]
[Pancreatic kallikrein, a protector of small intestine damage in post-ischemic toxemia]
[Physiological and pathological significance of plasma prekallikrein in obstetrics]
[Physiopathology of kinin forming system in reproduction]
[Urinary kallikrein quantity and activity of normal pregnant women and toxemia patients in third trimester]
Transfusion Reaction
Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system.
Trypanosomiasis, African
The role of kallikrein in the pathogenesis of African trypanosomiasis.
Typhoid Fever
Plasma kallikrein activation and inhibition during typhoid fever.
Prekallikrein (Fletcher factor) deficiency in typhoid fever.
Ureteral Obstruction
Exogenous pancreatic kininogenase protects against renal fibrosis in rat model of unilateral ureteral obstruction.
Urinary Bladder Neoplasms
Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
Urticaria
A rapid method for functional determination of C1 esterase inhibitor in plasma.
Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2007.
Cutaneous and pulmonary reactivity in cholinergic urticaria.
Cutaneous reactions to kallikrein and histamine in patients with urticaria.
Cutaneous reactions to kallikrein, bradykinin and histamine in healthy subjects and in patients with urticaria.
Decreased plasma kallikrein 5 concentrations in patients with chronic spontaneous urticaria.
Kallikrein and urticaria.
Late-phase cutaneous reactions to platelet activating factor and kallikrein in urticaria.
Plasma kallikrein amidolytic activity in patients with urticaria.
The cutaneous reactions to kallikrein, prostaglandin and thurfyl nicotinate in chronic urticaria and the effect of polyphloretin phosphate.
Treatment of urticaria with a kallikrein inhibitor.
Use of a kallikrein inhibitor in the treatment of urticaria and hereditary angioneurotic edema.
[Activity of the prekallikrein-kallikrein system and characteristics of its regulation in various allergies]
Uterine Cervical Neoplasms
[Clinical studies of kallidinogenase in combined chemotherapy for cervical cancer]
Uterine Cervicitis
Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia.
Uveitis
Kallistatin Attenuates Experimental Autoimmune Uveitis by Inhibiting Activation of T Cells.
Vaccinia
Expression and sorting of rat plasma kallikrein in POMC-producing AtT-20 cells.
Study on the in vitro assay method for evaluating the inhibitory effect of various substances on the production of plasma kallikrein.
Varicocele
Kallikrein therapy of infertile men with varicocele and impaired sperm motility.
Seminal prostaglandins in men with subnormal sperm motility and therapeutic treatment.
Surgical repair versus medical treatment of varicocele in the rat: pharmacological manipulation of the varicocelized testicle.
The effect of pancreatic kallikrein on semen parameters of men with varicocele.
[Treatment of oligospermic patients with varicocele]
Vascular Calcification
Profile of genetic variations in severely calcified carotid plaques by whole-exome sequencing.
Vascular Diseases
Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity.
Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP.
Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes.
Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease.
Vascular Ring
Kallikrein release by vascular tissue.
Vascular System Injuries
Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats.
High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells.
Renal and Vascular Effects of Kallikrein Inhibition in a Model of Lonomia obliqua Venom-Induced Acute Kidney Injury.
Venous Thromboembolism
Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population.
[New antitoagulants]
Venous Thrombosis
Cardiovascular diseases in congenital prekallikrein deficiency: comparison with other chance-associated morbidities.
Genetic variants associated with deep vein thrombosis: the F11 locus.
Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.
Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice.
Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis.
Regulation of the f11, klkb1, cyp4v3 gene cluster in livers of metabolically challenged mice.
Role of Factor XIa and Plasma Kallikrein in Arterial and Venous Thrombosis.
Some haemostatic parameters in patients with deep and superficial venous thrombosis.
[Clinical experiences with padutin (Bayer) in retinal venous thrombosis; observations on the measurement of retinal vascular diameters.]
Ventricular Fibrillation
Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion.
Vision, Low
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central-Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study.
von Willebrand Diseases
Genetics of equine bleeding disorders.
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.